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1.1 Cardiac remodelling 
 
The life saving capacity of appropriate diagnostic imaging in cardiovascular diseases 
has inspired intensive research into cardiac remodelling. While cardiac remodelling has 
been well characterized using our traditional diagnostic tools, suprisingly little attention 
has been given to assessing these conditions with cardiac magnetic resonance (CMR) 
imaging. Hereby our task is to characterize systematically cardiac remodelling in an 
effort to create the bedrock to receive our contextualized results. 
Cardiac remodelling is a compensatory process caused by mechanical, neurohormonal 
and genetic factors leading to functional and structural changes of the heart (1, 2). The 
term cardiac remodelling was first used to describe maladaptive changes after 
myocardial infarction including scar formation, left ventricular dilation and geometrical 
changes with increasing spherical geometry (3). Similar changes in left and also right 
ventricular geometry may be present in cardiomyopathies. Moreover, certain 
geometrical and structural alterations observed in pathological cardiac remodelling may 
be also caused by physiological factors such as intensive and regular exercise (4). 
In case of pathological remodelling many molecular and cellular mechanisms are 
contributing to ventricular remodelling including increased oxidative stress, 
inflammation, vascular changes, myocyte loss and hypertrophy, fibrosis and alterations 





Figure 1: Potential pathological stimuli contributing to cardiac remodelling (5). 
 
Although cardiac remodelling represents a compensatory process, if persist, may lead to 
continuous progressive changes affecting cardiomyocytes, smooth muscle cells, 
endothelium and interstitial matrix. Left ventricular parameters representing cardiac 
remodelling (left ventricular end-diastolic, end-systolic volume, ejection fraction) are 
closely related to cardiovascular outcomes, and are feasible endpoints to evaluate the 
efficacy of pharmacological and non-pharmacological therapeutic options (6). 
 
1.2 Physiological remodelling in athletes 
 
The term remodelling originally reflected a maladaptation to an underlying pathology. 
As pathological volume and pressure overload leads to dilation and hypertrophy of the 
left ventricle, haemodynamic changes observed in highly trained athletes may lead to 
similar changes including both enlarged ventricles and increased wall thickness. 
Physiological cardiac remodelling as a response to regular and intensive physical 
training, is a well-known phenomenon. Physiological cardiac remodelling in athletes 
DOI:10.14753/SE.2020.2408
11 
was described first in the 19
th
 century by a physician using auscultation and percussion 
(7, 8). Modern imaging technologies enable a more detailed structural and functional 
characterization of the athlete’s heart (Figure 2). 
Physical training can be divided into two main categories based on its metabolic 
characteristics. According to Morganroth’s work on the differentiation between 
endurance and power athletes, dynamic or endurance training causes volume overload, 
while static or strength training leads to pressure overload resulting in chamber dilation 
and hypertrophy, respectively (9-11). As the majority of sports contain various degree 
of endurance and power training, more detailed classifications were established based 
on the static and dynamic components of sports (12). Literature data imply that many 
other factors may influence the degree and nature of the cardiac adaptation including 
gender, training intensity and duration, age, ethnicity and currently unknown factors (4, 
13-18). Therefore to establish the physiological upper limit of cardiac adaptation in an 
athlete may often cause difficulties in the clinical routine. The importance of this 
question arises from the fact that false positive diagnosis of cardiomyopathies may lead 
to unnecessary interruption of a professional’s sports career. On the other hand, 
unrecognized pathologies may cause sudden unexpected cardiac death in young 
competitive athletes. The annual incidence rate of sudden cardiac death (SCD) in 
athletes is about 0.7-3.0 per 100 000 young athletes under 35 years (19-24). The 
incidence of sudden cardiac death in athletes is higher than in non-athletes. Competitive 
sports activity enhances the risk of SCD by 2- to 3-fold, and a clear male predominance 
was observed with a 2.3-10-fold risk compared to women (19, 20). Beside male gender, 
older age and Afro‐Caribbean origin are all associated with an increased SCD risk (23-
28). The aetiology of SCD in young athletes varies in different studies depending 
mainly on geographical and ethnical differences. Based on North American data the 
leading cause of SCD is hypertrophic cardiomyopathy (HCM) (22, 25), while European 
data suggests a higher prevalence of arrhythmogenic right ventricular cardiomyopathy 
(ARVC), especially in the Veneto region of Italy (29). The limited existing data 
regarding the aetiology of SCD in Hungarian athletes suggest, that although the most 
common cardiomyopathy in this population is HCM, in athletes with aborted sudden 
cardiac death the underlying cause is most commonly ARVC highlighting the extremely 




Figure 2: Cardiac magnetic resonance images of an athlete: cine balanced steady-state 
free precession (bSSFP) images (A,B) and late gadolinium enhancement images (C, D) 
in long- and short-axis views. Heart and Vascular Center, Semmelweis University. 
 
As cardiomyopathies – mostly HCM and ARVC – represent a significant proportion of 
SCD cases in young athletes, attention has been focused on differentiation of these 
conditions from physiological cardiac remodelling. Diagnostic dilemmas may arise 
mainly in highly trained athletes where cardiac adaptation may reach a level, which can 
mimic cardiomyopathies (Figure 3). Structural and functional alterations including 
ventricular dilation, slightly decreased ejection function, and electrical alterations (such 
as potentially abnormal electrocardiogram (ECG) findings and variety of arrhythmias) 





Figure 3: The Grey zone of overlap between physiological and pathological 
remodelling causing diagnostic dilemmas (32). ARVC, arrhythmogenic right ventricular 
cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; 
LBBB, left bundle branch block; LV, left ventricular; LVH, left ventricular 
hypertrophy; LVNC, left ventricular noncompaction; MRI, magnetic resonance 
imaging;  RV, right ventricular. 
 
1.3 Pathological remodelling in cardiomyopathies 
1.3.1 Hypertrophic cardiomyopathy 
 
Hypertrophic cardiomyopathy is a genetic disorder manifesting in left ventricular 
hypertrophy in the absence of secondary causes with an estimated prevalence of 0.16-
0.29% (33-37). The hypertrophy is frequently asymmetrical. It predominantly involves 
the basal interventricular septum, but midventricular, apical, inferolateral, right 
ventricular involvement and concentric forms may occur. HCM is a single gene disorder 
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with an autosomal dominant pattern of inheritance caused by mutations in genes 
encoding sarcomere-associated proteins. Autosomal recessive and X-linked mutations 
are extremely rare and should raise the suspicion of HCM phenocopies (38, 39).   
Histological features include myocyte hypertrophy, myocyte disarray and interstitial 
fibrosis. According to the current guideline of the European Society of Cardiology 
(ESC) the diagnostic criterion of HCM in adults is a maximal end-diastolic wall 
thickness ≥15 mm in one or more left ventricular myocardial segments that is not 
explained solely by loading conditions (40). Other conditions such as aortic stenosis, 
arterial hypertension, athlete’s heart and different phenocopies including amyloidosis, 
Anderson-Fabry, Pompe disease, Danon disease or endomyocardial fibrosis may mimic 
HCM and can cause diagnostic difficulties (Figure 4).  
Patients may stay asymptomatic for decades despite the presence of severe hypertrophy. 
The most frequent symptoms are heart failure with preserved ejection fraction, chest 
pain, palpitations, presyncope, syncope and sudden cardiac death. The symptoms 
develop mainly due to diastolic dysfunction, left ventricular outflow tract (LVOT) 
obstruction, imbalance between myocardial oxygen supply and demand and arrhythmias 
related to cardiac remodelling with myocardial hypertrophy, myocyte disarray and 
fibrosis (41). 
The estimated annual SCD risk is approximately 0.5-2%. Patients after aborted sudden 
cardiac arrest caused by ventricular fibrillation (VF) or sustained ventricular tachycardia 
(VT), implantation of an implantable cardioverter defibrillator (ICD) as secondary 
prevention is strongly indicated (40, 42). ICD implantation for primary prevention is 
recommended in patients with at least one risk factor including unexplained syncope, an 
abnormal blood pressure response to exercise (hypotension), massive (≥30 mm) 
thickening of the interventricular septum or ventricular wall, a positive family history of 
HCM and SCD, multiple episodes of documented nonsustained VT using an extended 
(30-day) period of cardiac rhythm monitoring, and extensive (≥15% of left ventricular 
mass) late gadolinium enhancement (LGE) determined by CMR imaging. To simplify 
risk assessment, the European Society of Cardiology established the HCM Risk 
Calculator (40), baseline and periodic re-evaluation is recommended because of the 
progressive nature of the disease. Besides SCD prevention, therapeutic options represent 
symptomatic treatment including pharmacological or interventional therapy; current 




Figure 4: Cine bSSFP and late gadolinium enhancement images of HCM and HCM 
phenocopies: aortic stenosis (A), HCM (B), amyloidosis (C), Anderson-Fabry 
disease (D). Heart and Vascular Center, Semmelweis University. 
 
HCM patients participating in competitive sport are representing a high risk population 
(42, 43). Present guidelines recommend the disqualification of HCM patients from any 
competitive sports regardless of the presence or absence of major risk factors (44, 45). 
Pelliccia and his colleagues recently published a paper about athletes with HCM. In this 
small, mainly low risk HCM population, although cardiac symptoms and cardiac arrest 
occurred, the incidence of symptoms and events were not different between patients, 
who were dismissed and who continued their exercise programs (46). These 
controversial data suggest that only additional larger scaled studies with massive 
population of athletes diagnosed with HCM could accurately evaluate the characteristics 
of this unique population, and clarify the role of regular exercise in disease progression 
and clinical outcomes. 
Diagnosing HCM in athletes is challenging in the everyday clinical routine. The overlap 
between mild HCM phenotypes and pronounced left ventricular hypertrophy of an 
athlete offered a challenge in the process of identifying the accurate diagnosis in the 
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grey zone of hypertrophy many years ago. The algorithm aiming to resolve this problem 
is presented in Figure 5 (47). Although it may be helpful in some cases in athletes with 
possible HCM, however, some of the patterns (e.g. LV cavity, atrial enlargement) may 
not be useful. Recent literature implies that the clinical characteristics of athletes with 
HCM significantly differ from sedentary HCM patients (48), therefore it is crucial to 
establish new parameters and cut-off values which could help to diagnose athletes with 
HCM. 
 
Figure 5: Criteria to distinguish HCM and athlete’s heart in patients in the grey zone of 
hypertrophy. (47) CMR, cardiac magnetic resonance; ECG, electrocardiogram; HCM, 
hypertrophic cardiomyopathy; LV, left ventricular. 
 
1.3.2 Arrhythmogenic right ventricular cardiomyopathy 
 
Arrhythmogenic right ventricular cardiomyopathy is a genetic disorder resulting in 
fibrofatty infiltration of the myocardium (49). Although most commonly it affects the 
right ventricle, based on literature data the left ventricle is involved in more than 50% of 
the cases (50-52). The estimated prevalence of the disease (0.02-0.05%) displays 
relevant geographic differences (49). The diagnosis is based on the current Task Force 
DOI:10.14753/SE.2020.2408
17 
criteria (TFC) including global or regional right ventricular dysfunction, structural 
changes, tissue characterization, repolarization and depolarization abnormalities, 
arrhythmias and family history (Table 1) (53). 
 
Table 1: Revised Task Force Criteria for the diagnosis of ARVC, adapted from Marcus 
et al. (53) The diagnosis is fulfilled by the presence of 2 major, or 1 major plus 2 minor 
criteria or 4 minor criteria from different groups. Diagnostic terminology for revised 
criteria: definite diagnosis: 2 major or 1 major and 2 minor criteria or 4 minor from 
different categories; borderline: 1 major and 1 minor or 3 minor criteria from different 
categories; possible: 1 major or 2 minor criteria from different categories. PLAX, 
parasternal long-axis view; RVOT, right ventricular outflow tract; BSA, body surface 
area; PSAX, parasternal short-axis view; aVF, augmented voltage unipolar left foot 
lead; and aVL, augmented voltage unipolar left arm lead, SAECG, signal-averaged 
electrocardiogram. 
Category Major criteria Minor criteria 
I. Global or regional 
dysfunction and 
structural alterations 
By 2D echo: 
● Regional RV akinesia,  
dyskinesia, or aneurysm 
● and 1 of the following (end 
diastole): 
— PLAX RVOT ≥32 mm 
(corrected for body 
size [PLAX/BSA] ≥19 mm/m2) 
— PSAX RVOT ≥36 mm 
(corrected for body size 
[PSAX/BSA] ≥21 mm/m2) 
— or fractional area change 
≤33% 
By MRI: 
● Regional RV akinesia or 
dyskinesia or 
dyssynchronous RV contraction 
● and 1 of the following: 
— Ratio of RV end-diastolic 
volume to BSA ≥110 mL/m2 
(male) or ≥100 mL/m2 (female) 
— or RV ejection fraction ≤40% 
By RV angiography: 
● Regional RV akinesia, 
dyskinesia, or aneurysm 
By 2D echo: 
● Regional RV akinesia or 
dyskinesia 
● and 1 of the following (end 
diastole): 
— PLAX RVOT ≥29 to <32 mm 
(corrected for body size 
[PLAX/BSA] ≥16 to <19 mm/m2) 
— PSAX RVOT ≥32 to <36 mm 
(corrected for body size 
[PSAX/BSA] ≥18 to <21 mm/m2) 
— or fractional area change >33% 
to ≤40% 
By MRI: 
● Regional RV akinesia or 
dyskinesia or dyssynchronous RV 
contraction 
● and 1 of the following: 
— Ratio of RV end-diastolic 
volume to BSA ≥100 to <110 
mL/m2 (male) or ≥90 to <100 
mL/m2 (female) 




II. Tissue characterization 
of wall 
● Residual myocytes <60% by 
morphometric analysis (or <50% 
if estimated), with fibrous 
replacement of the RV free wall 
myocardium in ≥1 sample, with 
or without fatty replacement of 
tissue on endomyocardial biopsy 
● Residual myocytes 60% to 75% 
by morphometric analysis (or 50% 
to 65% if estimated), with fibrous 
replacement of the RV free wall 
myocardium in ≥1 sample, with or 
without fatty replacement of tissue 
on endomyocardial biopsy 
III. Repolarization 
abnormalities 
● Inverted T waves in right 
precordial leads (V1, V2, and V3) 
or beyond in individuals >14 
years 
of age (in the absence of 
complete right bundle-branch 
block QRS ≥120 ms) 
● Inverted T waves in leads V1 
and V2 in individuals >14 years of 
age (in the absence of complete 
right bundle-branch block) or in 
V4, V5, or V6  
● Inverted T waves in leads V1, 
V2, V3, and V4 in individuals >14 
years of age in the presence of 





● Epsilon wave (reproducible 
low-amplitude signals between 
end of QRS complex to onset of 
the T wave) in the right 
precordial leads (V1 to V3) 
● Late potentials by SAECG in ≥1 
of 3 parameters in the absence of a 
QRS duration of ≥110 ms on the 
standard ECG  
● Filtered QRS duration (fQRS) 
≥114 ms 
● Duration of terminal QRS <40 
μV (low amplitude signal duration) 
≥38 ms 
● Root-mean-square voltage of 
terminal 40 ms ≥20 μV 
● Terminal activation duration of 
QRS ≥55 ms measured from the 
nadir of the S wave to the end of 
the QRS, including R’, in V1, V2, 
or V3, in the absence of complete 
right bundle-branch block 
V. Arrhythmias ● Nonsustained or sustained 
ventricular tachycardia of left 
bundle-branch morphology 
with superior axis (negative or 
indeterminate QRS in leads II, 
III, and aVF and positive in lead 
aVL) 
● Nonsustained or sustained 
ventricular tachycardia of RV 
outflow configuration, left bundle-
branch block morphology with 
inferior axis (positive QRS in leads 
II, III, and aVF and negative in 
lead aVL) or of unknown axis 
● >500 ventricular extrasystoles 
per 24 hours (Holter) 
VI. Family history ● ARVC confirmed in a first-
degree relative who meets current 
Task Force criteria 
● ARVC confirmed 
pathologically at autopsy 
or surgery in a first-degree 
relative 
● Identification of a pathogenic 
mutation categorized as 
associated or probably associated 
with ARVC in the patient under 
evaluation 
● History of ARVC in a first-
degree relative in whom it is not 
possible or practical to determine 
whether the family member meets 
current Task Force criteria 
● Premature sudden death (<35 
years of age) due to suspected 
ARVC in a first-degree 
relative 
● ARVC confirmed pathologically 






As a progressive disease, ARVC is categorized into different phases: the early 
concealed phase, overt or electrical phase, and phase of right ventricular (RV) and 
biventricular failure. As one of the most arrhythmogenic cardiomyopathies, it often 
manifests as ventricular tachycardia or ventricular fibrillation. Heart failure may occur 
mainly in the advanced stage of the disease. Morphological and ECG changes may lack 
in early phase making the diagnosis even more difficult. Moreover, certain pathologies 
can mimic ARVC such as idiopathic right ventricular outflow tract (RVOT) 
tachycardia, sarcoidosis, myocarditis or even physiological cardiac remodelling called 
athlete’s heart. 
As approximately 50% of the patients with ICD experience appropriate therapy (54, 55), 
the extremely arrhythmogenic nature of the disease is not questionable. Numerous risk 
factors have been proposed for stratifying SCD risk and indication for ICD implantation 
as risk stratification represents a crucial point in the management of ARVC. The 
international Task Force consensus statement distinguishes between the following 
categoriws: high risk patients with aborted SCD due to VF, sustained VT, severe 
ventricular dysfunction (>10% annual mortality rate), intermediate risk patients with at 
least one major risk factor including syncope, nonsustained ventricular tachycardia 
(nsVT), moderate ventricular dysfunction, or at least one minor risk factor including 
mild ventricular dysfunction, heart, failure, young age, male gender, complex genotype, 
proband status, inducible VT/VF, extent of electroanatomic scar, or fragmented 
electrocardiograms on right ventricular (RV) endocardial voltage mapping (1-10% 
annual mortality rate) and low risk patients without risk factors (<1% annual mortality 
rate) (56). Antiarrhythmic drug therapy including sotalol, beta blockers and amiodarone 
are frequently used in ARVC patients to reduce VT burden, although the efficacy is still 
debated because of the controversies introduced in medical literature (57-59). 
In ARVC patients, intensive training is associated with higher risk of life-threatening 
arrhythmias and heart failure (60-63). Competitive sport activity was associated with a 
5-fold SCD risk in young adults with ARVC (19). Therefore, athletes with definite 
diagnosis of ARVC should not participate in competitive sports with the exception of 
low-intensity class 1A sports (45). As recent literature data imply, recreational sport 
activity shows no association with earlier onset of symptoms or increased risk of life-
threatening arrhythmias. Restriction in patients performing only recreational sport 
activity has not been established as of yet (64, 65). 
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Although researchers initially mainly focused on the left ventricle in the athletic cardiac 
adaptation, in the last decade healthcare professionals have turned their attention to 
understand the structural and functional changes in the right ventricle as well (66-69). 
La Gerche and his colleagues found a lower rate of desmosomal gene mutations in 
athletes with RV arrhythmias compared to non-athletes. They hypothesized that regular 
intensive exercise alone may lead to proarrhythmogenic RV remodelling identifyied as 
“exercise-induced ARVC” (70). 
Early diagnosis of ARVC is a difficult clinical scenario in highly trained athletes. 
Dilated right and left ventricles and decreased ejection fraction may be a consequence 
of regular high intensity training, and precordial T-wave inversions in both leads v1 and 
v2 are present in more than half of the athletes (Figure 6) (71). Therefore, further 
diagnostic criteria are warranted to be discovered to solve this critical clinical dilemma. 
 
 
Figure 6: CMR images and 12-lead ECG of a highly trained athlete (A, B) and an 
ARVC patient (C,D) representing the overlapping features such as right ventricular 





1.3.3 Dilated cardiomyopathy 
 
Dilated cardiomyopathy (DCM) is a condition characterized by left ventricular or 
biventricular dilation and impaired systolic function, where pressure overload or 
coronary artery disease alone does not explain the myocardial dysfunction (72, 73). The 
estimated prevalence is 0.04-0.4% showing significant race-related and geographical 
differences (74, 75). Approximately 30-40% of the cases are genetic, affecting genes 
encoding cytoskeletal, sarcomere and nuclear envelope proteins. Non-genetic causes 
include alcohol abuse, toxins, drugs, inflammation, tachyarrhythmias, metabolic or 
endocrine disturbances. Symptoms most commonly are related to heart failure, 
arrhythmias and thromboembolic events (76). 
The clinical diagnosis of DCM relies on non-invasive imaging. It has been defined by 
the presence of reduced systolic function (fractional shortening <25% or left ventricular 
ejection fraction (LVEF) <45%) and  left ventricular dilation (LVEDD >117% of the 
predicted value corrected for age and body surface area) after excluding any known 
causes of myocardial dysfunction (77). Advanced imaging modalities may play a role in 
the early detection of the disease by more precise function and volume assessment, the 
detection of strain abnormalities or the presence of LGE (78).  
The management mainly focuses on the change in LV size and function, arrhythmias 
and congestive symptoms. Main cornerstones of the pharmacological therapy of heart 
failure with reduced ejection fractions are angiotensin-converting enzyme inhibitors, β-
blockers, aldosterone antagonists, angiotensin receptor-neprilysin inhibitor and 
ivabradine in patient with sinus rhythm above 70/min. Symptomatic patients besides 
optimal medical therapy with wide QRS and left bundle branch block (LBBB) 
morphology may benefit from cardiac resynchronization therapy (CRT) (79). ICD for 
primary prevention is indicated in patients with reduced ejection fraction (EF <35%) 
despite optimal medical treatment (80). However, literature implies that arrhythmia 
burden is unrelated to LV dysfunction (81) and a subset of patient may present 
ventricular arrhythmia in the early phase of the disease. These patients are classified as 
“arrhythmogenic DCM” patients. Halliday and his colleagues have proven that the 
presence of midwall LGE identifies patients with high SCD risk even in the subgroup of 
DCM patients with LVEF≥40% suggesting that DCM patients with only mildly reduced 
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or preserved LVEF but with midwall LGE may also benefit from ICD implantation 
(82). 
Physiological cardiac remodelling caused by regular intensive training may mimic 
DCM. Up to 15% of the athletes have increased cardiac dimensions. Moreover LVEF 
may be reduced in 45% of highly trained elite athletes (15, 83). As competitive sport 
activity may increase the risk of SCD, symptomatic patients with DCM should not 
participate in most competitive sports with the exception of low-intensity sports (class 
1A sports such as billiards, bowling, cricket, golf) in selected cases (45). The precise 
evaluation of cardiac dimensions and ventricular function are crucial in these clinical 
scenarios (Figure 7).  
 
Figure 7: CMR images of a young water-polo player with preserved LVEF (50%). Four 
chamber cine image shows marked left ventricular dilatation (LVEDVi: 154 ml/m2, 
RVEDVi: 122 ml/m2), where the presence of mild midmyocardial septal LGE 
confirmed the suspicion of DCM. Heart and Vascular Center, Semmelweis University. 
 
1.4 Reverse remodelling 
1.4.1 Reverse remodelling in athletes – cardiac deconditioning 
 
The physiological cardiac adaptation to vigorous exercise, in normal conditions is a 
reversible process (Figure 8). In athletes with structural heart disease the ventricular 
dilation and/or hypertrophy may decrease, but will not completely return to normal. 
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Based on this observation, deconditioning may have an important role in the differential 
diagnosis between healthy athletes and cardiomyopathies (84-86).  
However, extreme forms of cardiac adaptation in athletes raised the suspicion that 
exercise-related adaptations in healthy athletes are not always completely reversible. 
The study by Pelliccia et al. reported incomplete reversal of pronounced LV dilatation 
after deconditioning and chamber enlargement persisted in 20% of the retired athletes 
after five years (84). 
  
Figure 8: LV wall thickness and LV end-diastolic cavity dimensions in elite athletes 
after a long-term detraining. (84) LV, left ventricular.  
 
Biffi et al. reported a significant decrease in the frequency and complexity of ventricular 
arrhythmias after deconditioning, suggesting that electrical remodelling is part of the 







Figure 9: Number of premature beats, couplets and nsVTs at peak training and after 
deconditioning in 70 athletes based on 24-h Holter electrocardiogram. (87) PVDs, 
Premature ventricular beats; nsVT, nonsustained ventricular tachycardia. 
 
Based on the fact, that reduction of the number of ventricular arrhythmias during 
detraining may be present in healthy athletes and athletes with cardiomyopathy, forced 
deconditioning in order to differentiate between pathology and physiological adaptation 
is not recommended (88). 
 
1.4.2 Reverse remodelling due to pharmacological and non-
pharmacological therapy 
 
Patients with reduced ejection fraction (both with ischaemic and non-ischaemic 
aetiology) may undergo remarkable reverse remodelling after heart failure therapy or 
even spontaneously (89). In the absence of a universal definition for reverse 
remodelling, most studies define it as an increase in LVEF ≥10% with a decrease in left 
ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume 
(LVESV). Many studies have proven that the improvement of LVEF and decrease in 







Figure 10: Survival curves of DCM patients show long-term prognostic impact of left 
ventricular reverse remodelling (93). LVRR, left ventricular reverse remodelling; D, 
death; HTx, heart transplantation. 
Identifying patients who may remodel and who may not would be essential to optimize 
patient management. Therefore identifying predictors of reverse remodelling has a 
significant clinical importance. It has been proven that baseline end-diastolic volume, 
but not baseline LVEF predicts reverse remodelling (93-95). Baseline left atrial volume 
and right ventricular function might be also a predictor in specific patient populations 
(96, 97). Kubanek et al. showed that in DCM patients with recent onset of heart failure 
symptoms, the extent of LGE and higher myocardial oedema ratio is an independent 
predictor of reverse remodelling (98). Other CMR-based studies failed to prove the 
predictive nature of LGE suggesting that larger trials with more objective criteria for 
identification of mid-wall fibrosis are greatly demanded (94, 99). 
Beside optimal medical therapy, cardiac resynchronization therapy (CRT) is an 
effective therapeutic option to achieve reverse remodelling in heart failure patients with 
reduced ejection fraction and wide QRS with LBBB morphology (79). Figure 11. 






Figure 11: Long- (A,C) and short-axis (B, D) CMR cine images in end-diastolic phase 
at baseline (A-B) and six months after CRT implantation (C,D) represent apparent 
reverse remodelling. Sphericity index decreased (3D sphericity index: 0.34 vs 0.17); 
relative wall thickness increased (0.38 vs 0.51) and LV volumes also decreased 
(LVESVi 98 vs 33 ml/m2; LVEDVi 129 vs 74 ml/m2). Generator (yellow arrow) and 
lead related artifacts (white arrow) do not significantly affect image quality. Heart and 
Vascular Center, Semmelweis University. 
 
While the rate of non-responders mainly depends on how CRT response is defined, 
approximately 30-40% of patients with guideline based CRT indication do not show a 
clear benefit after CRT implantation (100). Therefore, determining factors of outcome 





wider QRS duration is associated with reverse remodelling and better outcome (101). 
Other factors such as mechanical dyssynchrony assessed using echocardiography have 
been intensively studied. Although several single-centre studies have proven the role of 
imaging in prediction of CRT response (102-105), in a large multicenter setting, no 
single echocardiographic parameter was able to predict CRT response (106). Combining 
advanced imaging techniques such as echocardiography-based strain imaging and 
CMR-based scar identification may have benefit in predicting CRT response. 
Hopefully, an ongoing large multicenter prospective study on multimodality-imaging 
may elucidate controversial issues in previous research (107). 
Reverse remodelling represents a multilevel molecular, cellular and anatomic reversion 
towards a normal myocardial structure and function, and can manifest in myocardial 
recovery or remission. Further research may support our fundamental understanding of 
reverse remodelling’s nature and the underlying mechanisms. (108). 
 
1.5 Cardiac magnetic resonance imaging and its role in the 
assessment of cardiac remodelling 
 
Cardiac magnetic resonance (CMR) imaging is the gold standard non-invasive method 
to evaluate left and right ventricular volumes, mass and ejection fraction. Furthermore, 
it enables identification and precise quantification of myocardial scar tissue. 
Functional changes in cardiac remodelling can be characterized using CMR imaging for 
the assessment of left and right ventricular ejection fraction (LVEF, RVEF), and stroke 
volume (LVSV, RVSV).  Quantification of the left and right ventricular volumes, mass 
and ejection fraction is based on manual delineation of the endocardium and epicardium 
on the short-axis cine images in end-systolic and end-diastolic phase. Using 
conventional quantification techniques the volume in between the endo- and epicardial 
contour is considered to be myocardial mass, and the volume within the endocardial line 
is considered to be blood. Novel threshold-based quantification techniques enable the 
quantification of the trabeculae and papillary muscles. The semi-automatic threshold-
based algorithm allows us to estimate the spatially varying signal intensities of blood 





intensities above the specified threshold are considered to be blood, voxels with signal 
intensities below the threshold are considered to be myocardium. Quantification of 
papillary muscles and trabeculae may play an important role detailed volumetric 
assessment especially in conditions with hypertrophy such as in HCM or athlete’s heart. 
Moreover, it may also contribute to a significant reduction in time required for post-
processing (109). 
CMR is an excellent modality for measuring strain, but the majority of the strain 
analysis techniques required additional sequences. CMR-based deformation imaging 
therefore has not been widely used till the development of feature tracking analysis. 
This novel quantification technique enables the assessment of myocardial strain using 
the conventional balanced steady-state free precession (bSSFP) cine images, no 
additional image acquisition is required. The optimal myocardium blood contrast 
provides optimal definition of the endocardial layer, therefore endocardial features can 
be tracked through the cardiac cylcle similar to the speckle tracking technique (110). 
Feature tracking enables measurement of global and regional left and right ventricular 
strain parameters, mechanical dispersion and intraventricular dyssynchrony as well. 
Cardiac remodeling is not only characterized by functional, but also morphological 
changes. Changes in cavity size and mass can be measured as left and right ventricular 
end-diastolic volume (LVEDV, RVEDV), end-systolic volume (LVESV, RVESV) and 
myocardial mass (LVM, RVM). Alterations in ventricular geometry/shape can be 
described using geometric indices such as sphericity index, relative wall thickness or 
maximal end-diastolic wall thickness to left ventricular end-diastolic volume index ratio 
(EDWT/LVEDVi) and left ventricular mass to end-diastolic volume ratio. 
CMR also enables to detect structural changes of the heart by detecting scar formation 
and replacement fibrosis with late gadolinium enhancement technique (111). Ten to 
twenty minutes after gadolinium-based contrast administration, applying T1-wheighted 
inversion recovery gradient-echo sequences and nulling the normal myocardium – 
supressing the signal from healthy myocardium –, enables to differentiate normal tissue 
(dark) and fibrotic tissue (bright) (Figure 12). The localisation and pattern of the LGE 
allows us to differentiate between ischaemic and non-ischaemic aetiology as well as to 







Figure 12: Representation of LGE patterns characteristic for ischaemic and non-
ischaemic pathologies. Adapted by Karamitsos et al. (112). DCM, dilated 
cardiomyopathy; HCM, hypertrophic cardiomyopathy; LGE, late gadolinium 
enhancement; MI, myocardial infarction. 
Beside the diagnostic role, the presence of LGE also has an added value in risk 
stratification. The extent and localisation of fibrosis in different cardiomyopathies are 
associated with adverse clinical outcomes including heart failure and ventricular 
arrhythmias (113-116). Patients with LGE have a higher incidence of ventricular 
arrhythmias and adverse cardiac outcomes (117-119). Ventricular scar may act as a 
substrate of life-threatening arrhythmias, and detecting fibrosis using CMR imaging is 
becoming a part of the clinical work-up also in the field of sports cardiology. 
Previously, it was understood that existing myocardial fibrotic tissue represents definite 
pathology, but recent literature suggests that focal LGE in the insertion points with 
unknown significance may be present in asymptomatic athletes. Potential mechanism 
behind aspecific myocardial fibrosis in athletes may be caused by pressure overload, 
exercise-induced repetitive microinjuries, genetic predisposition or silent myocarditis 
(120). 
Advanced CMR techniques, such as native T1 mapping and calculation of extracellular 





physiological cardiac remodelling, especially in conditions with diffuse fibrosis (121, 
122). Despite the many advantages of CMR techniques, implanted cardiac devices may 
carry some limitations. In the past, performing CMR examination in patients with 
pacemaker, ICD, CRT or implantable loop recorders has been contraindicated due to 
safety concerns. Recent data suggest that implanted cardiac devices represent no 
absolute contraindication. Manufacturers started to develop MRI conditional systems. A 
prospective, randomized multicenter study has proven no MRI-related contraindication, 
no MRI-attributed pacemaker sensing or threshold changes were observed (123). 
Moreover, large clinical studies have proven that applying prespecified safety protocol 
and careful programming, thoracic and non-thoracic MR examinations even in patients 
with non-conditional PM or ICD are safe. Addressing the concerns that MR 
examination may lead to decreased sensing, impedance or increased capture threshold, 
large clinical studies have proved that these changes on device parameters are non-
significant. Cardiac events are very rare including power-on reset, especially in ICD 
devices with low battery life, but in case of appropriate programming and imaging, the 
CMR examination do not lead to serious adverse cardiac events (124, 125). As fractured 
or abandoned leads may increase the risk of heating, scanning in these cases is not 
recommended. In addition, it is recommended to avoid MR imaging within six weeks 
post device implantation. 
The technical improvement regarding devices, improved image quality and positive 
safety results of large trials will lead to further improvement of scanning patients with 
implanted cardiac devices. In case of relative contraindications for CMR examination, 
the benefits and potential risks should be carefully assessed. 
 
1.6 Electroanatomic mapping and its role in the assessment of 
cardiac remodelling 
 
Besides functional and morphological changes, cardiac remodelling is characterized by 
structural alterations of the left ventricle including scar formation. As scar tissue is a 





radiofrequency catheter ablation (RFCA) may play an important role in the treatment of 
malignant ventricular arrhythmias in patients with structural heart disease. 
Electroanatomic mapping (EAM) using various mapping systems enables the detection 
of pathological fibrous, fatty, or inflammatory infiltrates inside the myocardium and the 
identification of low voltage or dense scar areas in three-dimensional electroanatomic 
maps. It may facilitate mapping and RFCA of cardiac arrhythmias including macro-
reentrant VT (126). Accurate identification of the pathological substrate especially in 
DCM is difficult; literature is controversial regarding thresholds for abnormal bipolar 
and unipolar voltages. Several studies have suggested different cut-off levels for normal 
and abnormal bipolar and unipolar, endocardial and epicardial left ventricular voltage 
values obtained by EAM. Based on previously proposed cut-off values to detect 
pathological substrates, low voltage area is mainly defined as electrograms with a 
bipolar voltage <1.5 mV, while dense scar is usually defined as a bipolar voltage <0.5 
mV for the LV endocardium (127, 128). These thresholds are well validated in patients 
with ischaemic aetiology and although they are adopted for patients with DCM, only 
limited data support the validity of these cut-offs in DCM (129). Glashan and his 
colleagues analysed EAM for pathological substrate identification in DCM, and 
validated their findings by histology. They have concluded that pathological substrates 
in DCM fundamentally differ from substrates in patients with ischaemic aetiologies. 
Therefore the currently applied EAM approaches need to be redefined and take the 
extent and localisation of fibrosis into account (130). Even though there are fixed 
thresholds for EAM, many clinical cardiac electrophysiologist change these cut-off 
values in order to better delineate pathological substrates. 
As EAM provides a helpful tool in tissue characterization by reconstructing the VT circuits 
in structural heart diseases, it may contribute to improve outcomes of RFCA of ventricular 







2. Study aims 
 
The main goal of our study was to analyse the functional, morphological and 
mechanical changes during physiological and pathological remodelling and reverse 
remodelling with the help of different CMR techniques.  
 
2.1 Differentiation of pathological and physiological 
remodelling 
 
The first aim of our studies was to describe then compare characteristics of 
physiological and pathological remodelling in athletes as well in cardiomyopathy 
patients, and to investigate the clinical and CMR characteristics of elite athletes with 
cardiomyopathies. We aimed to establish CMR parameters and cut-off values which 
may help to differentiate pathological and physiological remodelling.  
 
2.2 Electro-anatomic and tissue characterization 
 
Second aim was to investigate structural and electrophysiological remodelling in DCM 
patients by performing tissue characterization using CMR and electroanatomic 
characterization using electroanatomic mapping. We aimed to compare the distribution 
of late gadolinium enhancement and electroanatomical substrate. We proposed to assess 
VT ablation outcome and factors wich may influence the success. 
 
2.3 Reverse remodelling assessment 
 
Third goal was to investigate reverse remodelling as an effect of cardiac 
resynchronization therapy in symptomatic heart failure patients despite optimal medical 
therapy with broad QRS and LBBB morphology applying biventricular pacing during 
CMR examination. We also aimed to investigate the differences in the left ventricular 






3.1 Study design and study populations 
3.1.1 Study design and study population of the Differentiation 
of pathological and physiological remodelling project 
 
This retrospective study was conducted in the Semmelweis University Heart and 
Vascular Center. Healthy highly trained athletes, athletic and sedentary HCM and 
ARVC patients were examined using cardiac magnetic resonance imaging.  
Non-athlete HCM patients (n=194, 50.2±13.6y, 108 male) with preserved ejection 
fraction (LVEF ≥50%) were consecutively enrolled. HCM was defined according to the 
current ESC guideline (40), as a maximal wall thickness ≥15 mm measured by CMR 
that is not explained solely by loading conditions. In 11% of our HCM patients who had 
wall thickness between 13–14 mm we evaluated other features including family history, 
electrocardiogram (ECG) and typical LGE pattern. Ten additional athletes (31±10y; 9 
male, 14.4±6.5 training hours/week) were examined during training or competition 
period with the suspicion of HCM, and the comprehensive clinical investigation 
confirmed the diagnosis.  
Non-athlete patients with definite diagnosis of ARVC (n=34, 40.5±13.4y, 22 male) 
were enrolled based on the revised Task Force Criteria (53). Eight additional highly 
trained athletes with ARVC (27.6±3.3y, 18.9±4.6 training hours/week, seven male) 
were enrolled, and the comprehensive investigation including resting ECG, ambulatory 
ECG monitoring, echocardiography, CMR and medical history confirmed the diagnosis.  
Healthy athletes free of any cardiovascular diseases without ECG abnormality 
suggesting structural heart disease were recruited. The athletic cohort was comprised 
from canoe and kayak paddlers, water-polo players, rowers, handball players, speed 
skaters, swimmers, athletics, tennis players, cross country skiers, basketball players or 
cyclists.  
Highly trained healthy athletes members of the National or Olympic Team (n = 150, 
24.2±4.8y, 101 male) with a minimum of 18 hours of training per week for at least the 





and 21.2±3.5 h, respectively) performing highly dynamic, and at least, moderate static 
sports served as a control group of the sedentary HCM patient group. 
Thirty-four highly trained healthy athletes with with a minimum of 15 hours of training 
per week for at least five years performing sports with high dynamic and static 
components (31.8 ± 6.1 years, 22 male, 18.6 ± 2.2 training h/week) served as a control 
group of the sedentary ARVC patient group. 
Ethical approval was obtained from the Central Ethics Committee of Hungary (5012-
0/2011-EKU (142/PI/11)). Informed consent was obtained from all individual 
participants included in the study. 
 
3.1.2 Study design and study population of Electroanatomic 
and tissue characterization project 
 
This retrospective study was conducted in the Heart Center University of Leipzig. DCM 
patients (n=50, 58±15y, 39 male) who underwent RFCA of sustained VT or ventricular 
premature beats (VPB) and CMR scan (<30 days prior the ablation) were enrolled. The 
inclusion of the patients was based on the morphological appearance of a dilated LV 
and reduced ejection fraction using separate LVEDVi and LVEF criteria for men and 
women (131). Patients with significant coronary artery disease were excluded, and in 
case of VPB only patients without improvement of the LVEF after ablation were 
included. The CMR and EAM data were analysed by two blinded investigators, a third 
investigator was responsible for the spatial alignment of the EAM and CMR. An 
interrogation of the implantable cardioverter-defibrillator (ICD) devices and Holter 
ECGs were used to follow-up. 
 
3.1.3 Study design and study population of Reverse 
remodelling project 
 
This prospective study was conducted in the Semmelweis University Heart and 





the current guidelines (symptomatic heart failure, LVEF ≤35%, New York Heart 
Association functional class II-III on optimal medical therapy for at least 3 months), 
complete LBBB and broad QRS (>150 ms) were prospectively recruited. All patients 
were in sinus rhythm and normal atrioventricular conduction. Exclusion criteria were 
any contraindications of CMR examination or CRT implantation. Patients meeting all 
inclusion criteria and with no exclusion criteria underwent the implantation of a 
commercially available MRI conditional CRT-P (n=5) or CRT-D (n=8) device. Baseline 
CMR scan with contrast material was performed 1-14 days before CRT implantation, 
and follow-up non-contrast CMR scan was performed at six months ± 14 days after 
CRT implantation during biventricular pacing (DOO) and right atrial pacing (AOO). 
Changes of device parameters (e.g., impedance, thresholds, sensing and battery voltage) 
were recorded pre- and post CMR scan. ProBNP was measured and a 12-lead ECG was 
perormed at baseline and follow-up. CRT response was defined as the followings: 1) 
super-response: decrease in LVESVi >30%, 2) response: decrease in LVESVi >15%, 3) 
non-response: decrease in LVESVi <15%.  
All patients provided written informed consent prior to enrolment. Approval was 
obtained from the local ethics committee (034309-006/2014/OTIG). 
 
3.2 Image acquisition and analysis 




CMR examinations were conducted on a 1.5 T MR scanner (Achieva, Philips Medical 
Systems, Best, The Netherlands) with a 5-channel cardiac coil. For the assessment of 
cardiac dimensions and functions, retrospectively-gated, balanced steady-state free 
precession (bSSFP) segmented cine images were acquired in 2-chamber, 4-chamber and 
LV and RV outflow tract views. Short-axis images with full coverage of the left and 
right ventricle were obtained. Late gadolinium enhancement (LGE) imaging was 





was injected at a rate of 2–3 ml/s through antecubital intravenous line. Contrast-
enhanced images were acquired using a segmented inversion recovery sequence with 
additional phase sensitive reconstructions in the same views used for cine images 10–20 
min after contrast administration. 
Images were evaluated with Medis QMass 7.6 quantification software (Medis Medical 
Imaging Software, Leiden, The Netherlands). Endocardial and epicardial contour 
detection was performed by a blinded expert observer manually on short axis cine 
images. Quantification of the left ventricular ejection fraction (LVEF), volumes 
(LVESV, LVEDV, LVSV) and myocardial mass (LVM) were performed using 
conventional quantification method (CQ) (Medis QMass 7.6). Left ventricular volumes 
and masses were standardized to body surface area (BSA). 
In nonathletic and athletic HCM patients and in a subgroup of athletes a threshold-based 
quantification method (TQ) (Medis QMass 7.6 MassK algorithm) was also performed 
(Figure 13). Using TQ the trabeculae and papillary muscles (TPM) were also 
quantified, the semi-automatic threshold-based algorithm allows us to estimate the 
spatially varying signal intensities of blood and muscle within an observer-provided 
epicardial contour. Voxels with signal intensities above the specified threshold are 
considered to be blood, voxels with signal intensities below the threshold are considered 






Figure 13: Conventional quantification (A,B,C,D) and threshold-based quantification 
method (E,F,G,H) in HCM (A,E), healthy athlete (B,F), healthy athlete with EDWT in 
the grey zone of hypertrophy (C,G) and athlete with HCM (D,H). 
 
Maximal end-diastolic wall thickness (EDWT) measurements were performed in a short 
axis slice perpendicularly to the myocardial center line excluding right ventricular 
trabeculation. Minimal EDWT was measured in the same slice as the maximal EDWT. 
To further characterize the left ventricular hypertrophy and geometry, sport indices were 
derived using both conventional and threshold-based quantification method, such as left 
ventricular maximal diastolic wall thickness to end-diastolic volume index ratio 
(EDWT(mm)/LVEDVi(ml/m
2
)) and left ventricular mass to end-diastolic volume ratio 
(LVM(g)/LVEDV(ml)). Using threshold-based quantification TPM% 
((TPM(g)/LVM(g) *100) was also established. 
In nonathletic and athletic ARVC patients and in a subgroup of healthy athletes 
additionally quantification of right ventricular ejection fraction (RVEF), volumes 
(RVESV, RVEDV, RVSV) and myocardial mass (RVM) were performed using 
conventional quantification method. Regional right ventricular akinesis, dyskinesis, 
dyssynchrony were qualitatively assessed. Global LV and RV strain analysis was 
performed based on cine images after manual contouring of the endocardial borders. 
Additionally, regional strain analysis for the right ventricular free wall was performed 
based on RV endocardial contours on 4CH-view, peak systolic longitudinal strain and 
strain rate values of the basal, midventricular and apical free wall were established 
(Figure 14). Average and minimal values of the measured regional strain and strain rate 







Figure 14. Regional free RV wall strain analysis of a healthy athlete (a) and a highly 
trained athlete with ARVC (b). Strain curves of the athlete with ARVC represent 
regional RV dyssynchrony and decreased longitudinal strain of the midventricular 
(white) and apical (blue) RV free wall. Segments of the RV free wall and regional strain 
values of these segments are presented with same colour. RV, right ventricular. 
 
3.2.2 Electroanatomic and tissue characterization project  
 
CMR imaging 
CMR examinations were conducted on a 1.5 T MR scanner (Philips Ingenia, The 
Netherlands). Balanced steady-state free precession (bSSFP) segmented cine images 
were acquired as described before. Three-dimensional, high-resolution LGE-CMR 
imaging was performed more than 10 min after the application of intravenous contrast 
(gadolinium- DTPA, 0.2 mmol/kg). Two different protocols were used for patients with 





three-dimensional LGE imaging: free breathing, navigator-gated image data acquisition, 
the measured in-plane spatial resolution was 1.4x1.4x4.0 mm which was reconstructed 
to 0.7x0.7x2.0 mm. For device patients, we used multi-slice two-dimensional LGE 
employing the wideband technique with a bandwidth of the pre-pulse of 3000 Hz and a 
frequency offset of +1000 Hz during breath holding. The scans were performed in 
single breath hold with a measured spatial resolution of 1.7x1.7x10 mm, and 
reconstructed to 1.3x1.3x10 mm. Image analysis was performed using IntelliSpace 
Portal 6, Philips Healthcare. LVEF, LVEDVi, LVESVi, LVSVi, and LVMi were 
evaluated based on short-axis images after manual contouring as described before. 
Images were evaluated qualitatively by an observer blinded to the electroanatomical 
map for the presence or absence, pattern (subendocardial, mid-myocardial, 
subepicardial, transmural) and regional distribution of LGE areas using standardized 
myocardial 17-segment model. Extent of the LGE and its volume were established, 
LGE positive areas were quantified by thresholding signal intensity using the full-width 
half maximum (FWHM) method that defines the enhanced area by using 50% of the 
maximum signal found within the enhanced area. 
 
 
Electro-anatomical mapping and electro-anatomical map adjustment 
Endo- and epicardial cardial detailed maps of the left ventricle were obtained during 
sinus rhythm or ventricular pacing using CARTO system (Biosense Webster Inc., 
Diamond Bar, CA) with a 3.5-mm open irrigated-tip catheter (Navistar Thermocool, 
Biosense Webster Inc.). Bipolar (bandpass filtered at 30 to 500 Hz) electrograms were 
recorded and displayed at 200 mm/s sweep speed. A detailed assessment of individual 
electrogram characteristics was made off-line. The perivalvular areas were excluded. 
The bipolar low-voltage areas were defined by the accepted thresholds for patients with 
ischaemic cardiomyopathy: 0.5–1.5 mV, dense scar area was defined as <0.5 mV. The 
distribution of the low-voltage areas was described based on the AHA (American Heart 
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Figure 15: AHA 17-segment model of the left ventricule. Circumferential polar plot of 
the 17 myocardial segments and the nomenclature. AHA, American Heart Association. 
 
The exits of the VTs were defined as sites showing the best best pace-mapping sites 
matching scores (based on 10 surface ECG channels) and S-QRS interval less than 
80ms during pacing. First, we matched the CMR images with the EAM low-voltage 
areas defined using the standard bipolar threshold of 1.5mV. In terms of anatomical and 
electrical concordance, good agreement was defined if both EAM (<1.5mV) and CMR 
overlapped in all segments. Partially good agreement was defined as an overlap between 
LGE and EAM (<1.5mV) in at least one corresponding segment or in anatomically 
adjacent segments. As a second step, if no agreement between LGE and EAM was 
observed, a manual adjustment of the EAM cut-off limits was performed to match with 
LGE areas. Particular attention was paid on the abnormal potentials and the ablation 
lines to make sure that they fall within the borders of the newly defined low-voltage 
areas. Finally, the surface areas of the redefined low-voltage areas were measured and 
the maximal surface area on the endocardial or the epicardial surface was compared 
with the amount of the LGE mass and its distribution. The endpoint of acute success 
after ablation was non-inducibility of any sustained monomorphic VT with programmed 
ventricular stimulation with up to three extra beats down to the effective refractory 
period or 200 ms. For patients with VPB, successful catheter ablation was defined as 







3.2.3 Reverse remodelling project 
 
CMR imaging 
CMR examinations were conducted on a 1.5 T MR scanner (Achieva, Philips Medical 
Systems, Best, The Netherlands) with a 5-channel cardiac coil. For the assessment of 
cardiac dimensions and functions, at baseline retrospectively-gated, balanced steady-
state free precession (bSSFP) segmented cine images were acquired in 2-chamber, 4-
chamber and LV outflow tract views. Short-axis images with full coverage of the left 
and right ventricle were obtained. At follow-up spoiled gradient echo (SGE) imaging 
was performed when the first acquired bSSFP cine images were found to be of 
suboptimal image quality. Additionally, high temporal resolution cine images with a 
temporal resolution of 50 phases per cardiac cycle were also acquired in 2-chamber, 4-
chamber and LV outflow tract views and in three short-axis slices (basal, mid, apical) at 
baseline and follow-up. At the follow-up scan whole body specific absorption rate 
(SAR) was restricted according to the prescription of the implanted devices. At baseline, 
late gadolinium enhancement (LGE) imaging was performed as described in the first 
project. A CMR expert trained in cardiac life support and a physiologist with cardiac 
device expertise were present during the follow-up CMR examination. Cardiac rhythm, 
blood pressure and pulse oximetry were monitored from the time of device 
programming until reprogramming of baseline values using Invivo Precess 3160, 
Philips Medical Systems, Best, The Netherlands. 
Image analysis was performed using Medis Suite 3.0 software (Medis Medical Imaging 
Systems, Leiden, The Netherlands). Assessment of cardiac dimensions and functions 
were performed on short-axis cine image as described earlier. Additionally, remodelling 
parameters, such as 2D sphericity index (end-diastolic SA/LA diameter), 3D sphericity 
index (ESV/(4/3x π*(end-diastolic LA diameter/2)3) and relative wall thickness were 
calculated (2xEDWT/end-diastolic LA diameter). Quantitative deformation assessment 
was performed based on the manually endocardially contoured cine images using 
dedicated feature tracking quantification software (Medis Suite 3.0 QStrain, Leiden, 
The Netherlands). Global longitudinal (GLS), circumferential (GCS) and radial (GRS) 





was assessed by mechanical dispersion as the standard deviation of time to peak 
longitudinal (SD long TTP) and circumferential strain (SD circ TTP) in 16 LV 
segments. Regional left ventricular dyssynchrony was assessed by the maximum 
differences in time between peak septal and lateral transversal displacement based on 
regional strain analysis. Allowing comparisons between patients with different heart 
rates, regional LV dyssynchrony is expressed in ms adjusted to a standard cardiac cycle 
length of 1000 ms. The presence and localization of LGE was evaluated on baseline 
scans by an experienced reader. 
 
Device interrogation and programming 
Device interrogation was performed prior to CMR examination, in between different 
pacing modes and finally before patient discharge to record device parameters and 
verify system integrity. In order to achieve resynchronization therapy during image 
acquisition, the Medtronic devices were programmed manually according to Medtronic 
Field Technician’s recommendations as these CRT devices are not able to perform 
biventricular pacing in MRI safe mode. DOO pacing was programmed with baseline 
paced atrioventricular delay (PAV), ventriculoventricular (V-V) delay and left 
ventricular pacing parameters. Right ventricular and right atrial pacing energy was 
programmed to high output (5.0 V/1.0 ms) and bipolar pacing while baseline left 
ventricular pacing was not modified to avoid phrenic nerve 
stimulation. Tachyarrhythmia detection and therapy was suspended in defibrillators and 
baseline pacing rate was programmed to 10 beats per minute above the patient’s 
intrinsic sinus rate. SureScan mode OFF, the Medtronic Solara CRT-P device switches 
to magnet mode in the magnetic field. In magnet operation and pre-RRT battery status 
the device changes to asynchronous pacing with the programmed baseline ventricular 
pacing configuration and 85/min base rate. In order to obtain resynchronization, Solara 
CRT-P devices were programmed to 85/min DOO mode without any changes to the 
pacing intervals before CMR examination. Atrial pacing was performed by SureScan 
mode (AOO), and base rate was the same as in the DOO pacing configuration in both 
groups. Biotronik Intica 7 HF-T device was implanted in one patient. In this special 





DOO MRI safe mode was programmed to obtain biventricular pacing (70/min base rate, 
100 ms PAV, simultaneous V-V pacing). As MRI safe mode does not include AOO 
pacing as an option, pacing off option was used to mimic AOO mode. 
 
3.3  Statistical analysis 
3.3.1 Statistical analyses (Differentiation of pathological and 
physiological remodelling project) 
 
All continuous variables are expressed as mean ± standard deviation, categorical 
variables are expressed as percentages. When comparing HCM patients and athletes, 
between-groups comparisons of CMR parameters and sport indices were based on least-
squares linear regression if normality assumptions were satisfied and median regression 
otherwise. Models were stratified by HCM when comparing males versus females, and 
stratified for sex when comparing HCM patients versus athletes (i.e., practically, 
pairwise comparisons were made). Adjustment for age and heart frequency was applied 
by including these terms in the models as explanatory variables. When comparing 
ARVC patients and athletes, between-group comparisons were performed with the 
unpaired Student’s t test or Mann–Whitney U-test where appropriate. For area under the 
curve (AUC), a value of 0.9–1.0 was considered excellent, 0.75–0.9 good, 0.6–0.75 
moderate and 0.5–0.6 poor. Diagnostic accuracy of CMR parameters was evaluated 
using receiver operating characteristic (ROC) curve analysis. Cut-off values were set to 
maximize the proportion of subjects correctly classified. P-values <0.05 were 
considered to indicate statistical significance. Statistical analysis was performed using 
MedCalc software (version 17.9 Ostend, Belgium). 
 
 







The data structure has been tested with Shapiro–Wilk test for normal distribution. 
Continuous variables with normal distribution are reported as mean ± standard 
deviation, whereas categorical variables are reported as absolute numbers and 
proportions. Dependent on its structure, groups were compared with test Student’s t-test 
or Mann–Whitney U-test. Bivariate correlation analysis was performed using the 
correlation coefficient of Spearman. A double-sided p ≤0.05 was considered statistically 
significant. Statistical analysis was performed using the software SPSS 20.0 (IBM, 
Armonk, NY, USA). 
 
3.3.3 Statistical analyses (Reverse remodelling project) 
 
Continuous variables were reported as mean and standard deviation, and categorical 
variables as frequency and percentages. Between–group comparisons were performed 
using paired Student’s t-test or Wilcoxon test where appropriate. Pearson correlation 
coefficient was used to measure of the strength of the association between LV 
dyssynchrony and remodelling parameters. A p-value of ≤0.05 was considered 
statistically significant. Statistical analysis was performed using MedCalc software 







4.1 Results of the Differentiation of pathological and 
physiological remodelling project 
4.1.1 HCM and athlete’s heart 
4.1.1.1 Baseline characteristics 
 
HCM patients  
Twenty-eight percent and 30% of our HCM patients had positive family history for 
sudden cardiac death or HCM, respectively. Twenty-seven percent of HCM patients 
reported syncope and 32% palpitation. Only 55% had positive Sokolow or Cornell 
index, 82% showed T-wave inversion. Seventy-five percent (n=143) of HCM patients 
demonstrated LGE, mainly in the hypertrophic segments (80%) localized to the septum 
and anterior wall, in the right ventricular insertion points (55%), or only mild 
enhancement in the hypertrophic segments (19%). In our study population LGE showed 
excellent positive predictive value (𝑃𝑃𝑉 =
143
143+0
∗ 100 = 100%) but low negative 
predictive value (𝑁𝑃𝑉 =
108
108+47
∗ 100 = 70%). 
 
Healthy athletes 
None of our healthy athletes had positive family history of sudden cardiac death or 
HCM, all of them were asymptomatic. Seventy percent of athletes showed J-point 
elevation, 27% Sokolow or Cornell index positivity. Three athletes had T-wave 
inversion in more than one contiguous leads, all of them in V1-V3 leads without signs 
of left ventricular hypertrophy. None of the athletes showed pathological Q wave or ST-
depression, and none of them showed any LGE (n=108). 
 
Athletes with HCM 
Ten additional athletes (31±10y; nine male, 14.4±6.5 training hours/week, football 
(n=3), basketball (n=2), snowboard (n=1), pentathlon (n=1), kayak (n=1), water-polo 





because of the suspicion of HCM, where the comprehensive investigation including 
resting ECG, ambulatory ECG monitoring, echocardiography, CMR, medical and 
family history confirmed the diagnosis. No secondary cause of left ventricular 
hypertrophy was observed, and following 3-months training cessation only blunted or 
no deconditioning effect was observed: LVMi and EDWT remained in the pathological 
range. EDWT measured by CMR was 17.7±2.7 mm, five of them showed EDWT 
between 13-16 mm (Table 2). 
Table 2: Left ventricular CMR parameters of athletes with HCM assessed using 
conventional (CQ) and threshold-based (TQ) quantification. EDWT, maximal end-
diastolic wall thickness; Max/min EDWT, maximal to minimal end-diastolic wall 
thickness ratio; LV, left ventricular; EF, ejection fraction; ESVi, end-systolic volume 
index; EDVi, end-diastolic volume index; SVi, stroke volume index; Mi, mass index; 
EDWT/LVEDVi, maximal end-diastolic wall thickness to left ventricular end-diastolic 
volume index ratio; LVM/LVEDV, left ventricular mass to left ventricular end-diastolic 
volume ratio, TPM, trabeculae and papillary muscles; TPMi, trabeculae and papillary 
muscles corrected to BSA; TPM% trabeculae and papillary muscles expressed as the 
percentage of total LV myocardial mass 
 Athletes with HCM (n=10)  
mean ± SD 
EDWT (mm) 17.7±2.7 
Max/min EDWT 2.28±0.52 
Conventional quantification 
















LVMTQ/LVEDVCQ (g/ml) 0.94±0. 13 
Threshold-based quantification 
















LVMTQ/LVEDVTQ (g/ml) 1.62±0.28 









All of the athletes with HCM showed at least one pathological ECG finding according 
to the 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy (15). Eight patients had positive Sokolow or Cornell index and nine 
patients showed T wave inversion on 12-lead ECG. Only two patients showed diastolic 
dysfunction on echocardiography. Apical HCM morphology was confirmed in four 
patients. Only four patients showed LGE in the hypertrophic regions and/or in the right 
ventricular insertion points (Figure 17). 
 
 
Figure 17: LGE images in 4-chamber (A,C,E) and 2-chamber views (B,D,F) of athletes 





midmyocardial patchy LGE (C,D) and apical HCM with mild LGE in the hypertrophic 
segments (D-F). White arrows show regions with high signal intensity representing late 
gadolinium enhancement. Heart and Vascular Center, Semmelweis University. 
 
4.1.1.2 Comparison of left ventricular CMR parameters in 
healthy athletes and HCM patients evaluated using 
threshold-based and conventional quantification method 
Both male and female HCM patients had higher EDWT compared to athletes (22.1 mm 
vs 12.6 mm; 19.7 vs 10.4, respectively), 14.8% of male HCM patients, 47.5% of male 
athletes, 19.8% of female HCM patients and 4.1% of female athletes were in the grey 
zone of borderline hypertrophy (EDWT 13-16 mm). Thirty-five percent of our male 
rowers, 52% of canoe and kayak paddlers and 54% of water-polo players showed 
EDWT between 13-16 mm. 
Using conventional quantification sport indices EDWT/LVEDViCQ and 
LVMCQ/LVEDVCQ were significantly lower in athletes compared to HCM patients. 
Using threshold-based quantification method, LVMiTQ was lower in male athletes 
compared to HCM patients, TPM and TPM% were also lower in athletes than in HCM 
patients. Sport indices EDWT/LVEDViTQ and LVMTQ/LVEDVTQ were also lower in 
athletes compared to HCM patients. Compared to female athletes, male athletes showed 
significantly higher maximal EDWT, left ventricular volumes, mass and LVM/LVEDV 
using both conventional and threshold-based quantification method. TPMi was also 
higher and TPM% was lower in male athletes, and LVEF showed no significant 






Table 3: Left ventricular CMR parameters in the four subgroups evaluated using 
conventional (CQ) and threshold-based (TQ) quantification. EDWT, maximal end-
diastolic wall thickness; Max/min EDWT, maximal to minimal end-diastolic wall 
thickness ratio; LV, left ventricular; EF, ejection fraction; ESVi, end-systolic volume 
index; EDVi, end-diastolic volume index; SVi, stroke volume index; Mi, mass index; 
EDWT/LVEDVi, maximal end-diastolic wall thickness  to left ventricular end-diastolic 
volume index ratio; LVM/LVEDV, left ventricular mass to left ventricular end-diastolic 
volume ratio evaluated using CQ and TQ. 
*
significantly different from male HCM, 
#
significantly different from female HCM, 
¥




mean ± SD 
Male HCM  
(n=108) 
mean ± SD 
Female 
athlete (n=49) 
mean ± SD 
Female HCM 
(n=86) 












































































































































 x 100 (%) 19.0±3.7
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4.1.1.3 Diagnostic accuracy of sport indices to differentiate 
HCM and athlete’s heart 
 
We compared the efficiency of CMR based sport indices in differentiation of athlete’s 
heart from HCM evaluated using conventional and threshold-based methods. Although 
efficiency of EDWT/LVEDVi evaluated using TQ and CQ showed no significant 
difference, LVM/LVEDV evaluated using TQ performed significantly better than CQ in 
both males and females (Figure 18). Both sport indices established using TQ performed 
significantly better than max/min EDWT (p <0.05). Cut-off value for max/min 
EDWT>2.4 (AUC 0.900) discriminated with a sensitivity of 81.4% and a specificity of 
86.7 %. 
 
Figure 18: ROC curves visualizing correct identification of HCM among male and 
female subjects, p values represent the difference in diagnostic performance between 





end-diastolic wall thickness to left ventricular end-diastolic volume index ratio; 
LVM/LVEDV, left ventricular mass to left ventricular end-diastolic volume ratio; AUC, 
area under the curve. 
 
Sport indices showed also high diagnostic accuracy in the male subgroup with EDWT 
between 13-16 mm, LVM/LVEDV evaluated using TQ performed significantly better 
than CQ (Figure 19).  
 
Figure 19: ROC curves visualizing correct identification of HCM among subgroup of 
individuals with EDWT between 13–16 mm, p values represent the difference in 
diagnostic performance between conventional and threshold based quantification 
methods. EDWT/LVEDVi, maximal end-diastolic wall thickness to left ventricular end-
diastolic volume index ratio; LVM/LVEDV, left ventricular mass to left ventricular 
end-diastolic volume ratio; AUC, area under the curve. 
 
Cut-off value for ratio of EDWT/LVEDViCQ less than 0.14 mm×m
2
/ml and cut-off 
value for EDWT/LVEDViTQ less than 0.17 discriminated between physiological and 
pathological LV hypertrophy with a sensitivity of 99.5% and 99.0%, a specificity of 
98% and 99.3%, respectively. Cut-off value for ratio of LVM/LVEDVCQ less than 0.82 
mm×m
2
/ml and cut-off value for LVM/LVEDVTQ less than 1.27 discriminated between 
physiological and pathological LV hypertrophy with a sensitivity of 77.8% and 89.2%, 
a specificity of 86.7% and 91.3%, respectively (Table 4). Despite the apparent gender-
specific differences in cardiovascular sport adaptation, our cut-off values regarding 





Table 4: Cut-off values for optimised sensitivity and specificity. EDWT/LVEDVi, 
maximal end-diastolic wall thickness  to left ventricular end-diastolic volume index 
ratio; LVM/LVEDV, left ventricular mass to left ventricular end-diastolic volume ratio 
evaluated using conventional (CQ) and threshold based quantification (TQ), AUC, area 
under curve, sens, sensitivity; spec, specificity; PPV, positive predictive value; NPV, 
negative predictive value. 
 Cut-off 
value 








>0.14 0.998 99.5 98.0 95.5 99.3 99.4 
LVMCQ/LVEDVCQ (g/ml) 






>0.17 0.999 99.0 99.3 99.5 98.7 99.4 
LVMTQ/LVEDVTQ (g/ml) 
>1.27 0.948 89.2 91.3 93.0 86.7 94.4 
 
According to our cut-off values EDWT/LVEDViCQ, EDWT/LVEDViTQ, 
LVMCQ/LVEDViCQ and LVMTQ/LVEDViTQ were in the pathological range in nine, 







Figure 20: Clinical characteristics of athletes with HCM including pathological ECG 
findings, diastolic dysfunction evaluated using echocardiography and EDWT, 





4.1.2 ARVC and athlete’s heart 
4.1.2.1 Baseline characteristics 
 
ARVC patients and healthy athletes 
Thirty-four non-athlete ARVC patients were enrolled (40.5±13.4 years, 22 male). 
Diagnosis of ARVC was based on the current TFC. Positive family history for SCD or 
ARVC was present in 18% of the ARVC patients, 59% had recorded sustained 
ventricular tachycardia (VT) or ventricular fibrillation (VF), and aborted sudden cardiac 
death was reported in 12%. Average Task Force score (major = 2 points, minor = 1 
point) was 4.9 points. Biventricular involvement was observed in 71%. LGE was 
present in 69%, in 14 patients only in the LV, in two patients only in the RV, and six 
patients demonstrated biventricular LGE (Figure 16). 
 
 
Figure 16: Biventricular LGE in ARVC presenting with biventricular involvement. 
White arrows show regions with high signal intensity representing late gadolinium 
enhancement. Heart and Vascular Center, Semmelweis University. 
 
None of the healthy athletes had positive family history of sudden cardiac death or 
ARVC, all of them were asymptomatic. None of the healthy athletes had any ECG 
abnormality suggesting structural heart disease, none of them showed T-wave inversion 
in more than 1 continuous leads, Q wave inversion or ST-depression. 81% of athletes 
showed J-point elevation, 19% Sokolow or Cornell index positivity for left ventricular 





or late gadolinium enhancement (LGE). RVEDVi was in the proposed range of the 
major TFC (>110 ml/m
2
 in males, >100 ml/m2 in females) in all healthy male athletes 
and 83.3% of healthy female athletes. RVEDVi of the remaining female athletes were in 
the proposed range of the minor TFC (>90 ml/m
2
 in females). None of the athletes 
showed RVEF ≤45%, RVEF between 45 and 50% was observed in five cases (14.7%, 
three male and two female athletes). 
 
Athletes with ARVC 
In eight additional athletes (18.9±4.6 training h/week, triathletes n=3, cyclists n=2, 
swimmers n=2, football player n=1) the comprehensive investigation including resting 
ECG, ambulatory ECG monitoring, echocardiography, CMR and medical history 
confirmed the diagnosis. In three cases, CMR examination was repeated after training 
cessation for 2–3 months. Successful deconditioning effect was observed on LV values 
(LVEDVi: 127.4±5.4 ml/m
2
 vs 109±10.6 ml/m
2
; LVMi: 93.4±16.7 vs 73.5±9.4 g/m
2
). 
However, only blunted deconditioning effect was observed on RV values, and RVEDVi 
remained in the pathological range (169.7±10.5 ml/m
2
 vs 137.3±17.1 ml/m
2
). Four 
athletes had documented sustained VT or VF, and aborted SCD was reported in two 
cases. None of them had positive family history for ARVC or SCD. Two athletes did 
not fulfil any repolarization or depolarization criteria, T-wave inversion (TWI) in lead 
V1–V2 and in V1–V3 leads was observed in one and four athletes, respectively. One 
patient had complete right bundle branch block. Epsilon wave was observed in 3 
patients. Average Task Force score was 5.4 points. Biventricular involvement was 
confirmed in three patients (defined by left ventricular LGE and/or LVEF <50). Three 
patients showed LGE: two of them biventricular and one solely left ventricular LGE. 









4.1.2.2 Comparison of CMR parameters between healthy 
athletes and ARVC patients 
 
Healthy athletes showed higher LVEDVi, LVSVi, LVMi, RVSVi and RVMi than non-
athlete ARVC patients. No significant difference was found between athletes and non-
athlete ARVC patients regarding the RVEDVi. Both RVEF and LVEF were 
significantly lower in ARVC patients compared to healthy athletes (Table 5). 
 
Table 5: Baseline characteristics and conventional left and right ventricular CMR 
parameters in healthy athletes, ARVC patients and athletes with ARVC. Values are 
expressed in mean ± SD. BSA, body surface area; LV, left ventricular; RV, right 
ventricular; EF, ejection fraction; ESVi, end-systolic volume index; EDVi, end-diastolic 
volume index; SVi, stroke volume index; Mi, mass index. 








 Athletes (n=34) 
 mean ± SD 
ARVC (n=34)  
mean ± SD 
 Athletes with ARVC 
(n=8) mean ± SD 
Age (ys) 31.8±7.7 40.5±16.3*  27.6±3.3 
BSA (m
2
) 1.94±0.19 1.88±0.21  1.86±0.13 
Male (%) 65 65  87.5 
Heart rate (bpm) 55.0±7.6 63.0±7.4***  58.5±8.8 
LVEF (%) 57.6±4.7 52.0±11.2*  60.1±3.1 
LVESVi (ml/m
2
) 50.3±10.9 50.9±20.0  50.2±8.3 
LVEDVi (ml/m
2
) 117.8±17.3 107.2±22.5*  121.1±17.4 
LVSVi (ml/m
2
) 67.6±9.4 54.0±13.1***  72.6±10.9 
LVMi (g/m
2
) 82.9±16.1 58.2±12.8***  87.2±16.3 
RVEF (%) 55.7±4.6 40.5±13.6***  47.5±3.8 
RVESVi (ml/m
2
) 55.6±11.9 88.3±45.1***  76.2±10.8 
RVEDVi (ml/m
2
) 123.6±17.0 142.7±47.5  146.1±25.7 
RVSVi (ml/m
2
) 68.6±9.1 52.7±17.5***  70.0±15.1 
RVMi (g/m
2







Right ventricular global longitudinal strain (RV GLS) was decreased in the ARVC 
group compared to athletes. Regional longitudinal strain and strain rates of the RV free 
wall are presented in Table 6.  Right ventricular mid strain, RV mid strain rate, and 
average and minimal values of the measured regional strain and strain rate values 
showed significant difference between the two groups.  
 
Table 6: Global and regional strain and strain rate values of healthy athletes, ARVC 
patients and athletes with ARVC. Values are expressed in mean ± SD. GLS, global 
longitudinal strain; GCS, global circumferential strain; GRS, global regional strain; LV 
left ventriular. 








 Athletes (n=34) 
mean ± SD 
ARVC (n=34)  
mean ± SD 
 Athletes with ARVC 
(n=8) 
mean ± SD 
Global left and right ventricular strain 
LV GLS -22.0±3.4 -20.4±5.0  -24.9±1.4 
LV GCS -30.5±6.0 -26.3±.8*  -35.6±5.7 
LV GRS 57.6±14.5 49.8±49.9  71.4±11.2 
RV GLS -25.6±3.9 -20.4±7.6**  -21.3±3.9 
Regional longitudinal strain and strain rate values of the RV free wall 
RV basal strain -34.5±8.6 -30.9±11.8  -35.6±8.3 
RV mid strain -31.5±10.2 -20.0±13.4***  -21.5±4.9 
RV apical strain -30.9±8.0 -24.6±11.6**  -19.7±11.1 
RV average strain -32.3±5.0 -25.1±9.3**  -25.6±3.0 
RV min strain -24.0±7.2 -15.2±9.0***  -15.4±7.1 
RV basal strain rate -1.74±0.59 -1.52±0.97*  -1.61±0.63 
RV mid strain rate -1.37±0.56 -1.04±0.68**  -1.05±0.22 
RV apical strain rate -1.33±0.40 -1.17±0.56  -0.96±0.34 
RV average strain rate -1.48±0.38 -1.24±0.59 *  -1.21±0.28 







4.1.2.3 Diagnostic accuracy of CMR parameters and feature 
tracking based deformation imaging to differentiate 
ARVC and athlete’s heart 
Establishing AUC values for the CMR parameters RVEF showed good accuracy (AUC 
=0.830), whereas RVEDVi failed as a discriminator between ARVC and athlete’s heart 
(AUC =0.599). Cut-off value for RVEF ≤45.8 discriminates between ARVC and 
athlete’s heart with a sensitivity of 68% and a specificity of 100%. RV mid strain, 
average and minimum of the measured regional strain values demonstrated good 
discrimination between athlete’s heart and ARVC. We investigated whether establishing 
gender-specific cut-off values may influence the diagnostic accuracy, but comparing 
male and female ROC curves for CMR parameters with the highest diagnostic accuracy 
(RVEF, RV mid strain, RV average strain, RV min strain) showed no significant 
difference. These results suggest that gender-specific differences regarding these 
parameters are negligible, so we present cut-off values for both males and females. Cut-
off values for global and regional strain values are presented in Table 7. 
Table 7: Area under the ROC curves and cut-off values. Parameters showing good 
diagnostic accuracy appears in bold. EF, ejection fraction; EDVi, end-diastolic volume 
index; GLS, global longitudinal strain; GCS, global circumferential strain; GRS, global 







 Cut-off value AUC Sensitivity Specificity p 
  CMR Task Force criteria 
RVEF ≤45.8 0.830 67.65 100.00 0.0001 
RVEDVi >150.8 0.599 29.41 94.12 NS 
Global left and right ventricular strain values 
LV GLS >-17.7 0.596 32.35 94.12 NS 
LV GCS >-22.5 0.643 38.24 100.00 0.0386 
LV GRS ≤41.8 0.607 41.18 94.12 NS 
RV GLS >-20.1 0.726 50.00 97.06 0.0004 
Regional strain values of the RV free wall 
RV basal strain <-35.8 0.634 70.59 58.82 NS 
RV mid strain >-25.6 0.767 70.59 82.35 0.0001 
RV apical strain >-23.9 0.694 55.88 85.29 0.0042 
RV average strain >-29.4 0.772 73.53 76.47 0.0001 
RV min strain >-18.1 0.786 70.59 85.29 0.0001 
RV basal strain rate >-1.3 0.665 58.82 85.29 0.0195 
RV mid strain rate >-1,4 0.686 82.35 50.00 0.0045 
RV apical strain rate >-0.9 0.606 38.24 91.18 NS 
RV average strain rate >-1.13 0.665 52.94 88.24 0.0175 
RV min strain rate >0.8 0.702 55.88 82.35 0.0014 
We tested the established cut-off values for CMR parameters in the group of highly 
trained athletes with diagnosed ARVC. Applying these cut-off values, RVEF was in the 
pathological range in only three athletes with ARVC. Half of the athletes with ARVC 
showed normal RV GLS. Regional longitudinal strain and strain rate of the RV mid free 






Figure 21: Clinical characteristics of athletes with ARVC including pathological ECG 
findings, arrhythmias and myocardial fibrosis. Midventricular RV longitudinal strain 
and strain rate were in the pathological range based on our cut-off values in all of the 






4.2 Results of the Electro-anatomic and tissue characterization 
project 
4.2.1  Baseline characteristics 
 
Out of 147 patients with a phenotype of DCM who received catheter ablation for VA, 
50 suitable patients (age 58±15 y, 78% male) were identified. The mean LVEF was 
35.5%±12% and the mean LVEDVi was 121± 43ml/m
2
. Of them, 21 (44%) patients 
received RFCA for sustained VT, 22 (42%) for pleomorphic VPB and nsVT, and seven 
(14%) for VPB from the left ventricular outflow tract or aortic cusps. The median 
number of induced VTs (IQR) was two (1–3) VTs. Nine patients received at least 1 
cardioversion during ablation. The median number of cardioversions during ablation 
was 1 (IQR 0–3). Eight patients received amiodarone before ablation which was 
continued thereafter. Mean fluoroscopy time was 24±16.6 min. No patients were lost to 
follow-up. The baseline clinical characteristics and CMR/EAM data are presented in 
Table 8 and Table 9, respectively. 
 
Table 8: Baseline characteristics. Values are expressed as mean ± SD, numbers and 
percentage. ACEI/ARB, angiotensin-converting-enzyme inhibitor/angiotensin receptor 
blockers; CMR, cardiac magnetic resonance; ICD, implantable cardioverter-
defibrillator; nsVT, non-sustained ventricular tachycardia; VPB, ventricular premature 
beat; VT, ventricular tachycardia. 
Baseline characteristics All n=50 
Age (at CMR), y 58±15 
Female, n (%) 11 (22) 
Cause, n (%) 
    Familiar 2 (4) 
    Valvular 1 (2) 
    Myocarditis 10 (20) 
    Sarcoidosis 1 (2) 
    Idiopathic 36 (72) 
Arterial hypertension, n (%) 34 (68) 
Diabetes mellitus, n (%) 12 (24) 
Atrial fibrillation, n (%) 10 (20) 
Therapy 





   Statin, n (%) 12 (24) 
Antiarrhythmic drugs, n (%) 
   Flecainide 12 (24) 
   Sotalol 1 (2) 
   Amiodarone 11 (22) 
   Other 3 (6) 
Betablockers, n (%) 38 (76) 
ICD, n (%) 19 (38) 
Electrical storm, n (%) 9 (18) 
ICD shocks, n (%) 12 (24) 
Indication for ablation, n (%) 
   Sustained VT 21 (44) 
   VPB or nsVT 29(56) 
Table 9: CMR and EAMs characteristics. Values are expressed as mean ± SD or 
median, inter-quartile range (Q1–Q3).  BSA, body surface area; CMR, cardiac magnetic 
resonance; EAM, electroanatomical maps; EDV, end-diastolic volume; EF, ejection 
fraction; ESV, end-systolic volume; FWHM, full-width half maximum; IVS, 
interventricular septum; LGE, late gadolinium enhancement; LV, left ventricle; LVA, 
low-voltage area; LVM, left ventricular mass; PW, posterior wall. 
Procedural Data All n=50 
CMR 
EF, % 36±11.9 
IVS, mm 10±1.95 
PW, mm 9±1.85 








LGE Volume (%) 2.79±5.1 
LGE Mass (FWHM), g 3.1±5.9 
LVM, g 135±45 
EAM 
Minimal bipolar amplitude endo, mV 0.31±0.18 
Maximal bipolar amplitude endo, mV 12.4±4.7 
Minimal bipolar amplitude epi, mV 0.2±0.16 
Maximal bipolar amplitude epi, mV 11.2±5 
Bipolar LVA surface endo (< 1.5 mV), cm
2
 24.8±20.7 
Largest LVA (endo or epic) (<1.5 mV), cm
2
 16.5 (6.8 - 47) 
Largest LVA (endo or epic) (<0.5 mV), cm
2





4.2.2  Characteristics and distribution of the late gadolinium 
enhancement and electroanatomical substrate 
 
Late gadolinium enhancement was observed in 16 (32%) patients (LGE+). Epicardial 
LGE spreading to the mid-myocardial layers was observed in eight patients, only mid-
myocardial LGE was observed in five patients, and endocardial to mid-myocardial LGE 
in three patients. LGE was detected in 12 out of 19 (63%) patients with ICDs vs four out 
of 31 (13%) patients without ICD, which was a significant difference (p< 0.001). 
Furthermore, LGE was observed in 15 (71.4%) patients with sustained monomorphic 
VT, in one (4.8%) patient with pleomorphic nsVT and in none of the patients with VPB 
originating from the LV summit (p <0.0001). The most frequently enhancing segments 
were the basal inferolateral, inferior and inferoseptal segments: 2, 3, 4, 5, as well as 
segment 9. Furthermore, in the LGE+ patients, the best pace mapping sites with clinical 
VT were found in the basal anterior and anterolateral segments: 1 and 6. In 23 patients 
with low-voltage areas <1.5mV, 16 patients had sustained monomorphic VTs and the 
other seven patients had only VPB or nsVT. The most frequently affected segments in 
these patients were the basal anterior and anteroseptal (1 and 2) as well as the 
inferoseptal segments (3 and 4) at the endocardial surface. On the epicardial surface, the 
most frequently involved segments were 1, 5, 6, and 8. 
 
4.2.3  Agreement between late gadolinium enhancement and 
electroanatomical maps 
 
Among the 50 patients, 23 (46%) patients with low-voltage areas (LVA) (<1.5mV) and 
16 (32%) patients with LGE were identified. Presence of low-voltage areas without any 
evidence of LGE was observed in seven (14%) patients. In 27 (54%) patients neither 
LGE nor low-voltage areas in EAM were detected. In the 16 LGE+ patients, a good 
agreement between LGE and LVA (<1.5 mV) was observed in four (25%) patients, 





Regarding VT exit sites, the best pace-mapping sites were observed in segments with 
LGE in 12 out of 16 patients. In two patients, the best pace-mapping sites were located 
in anatomically adjacent LGE segments, and in two patients—in segments without 
evidence of LGE in CMR. The mean LGE (FWHM) mass was 10.6±6.2 g and the mean 
LGE as a percentage of the LV was 8.73%±5.4%. The largest low-voltage area (endo- 
or epicardially) with amplitude <1.5 mV had median (Q1–Q3) of 16.5 (6.8–47) cm
2
, 
whereas the largest dense scar area (endo- or epicardially) <0.5 mV had median (Q1–
Q3) of 4.4 (0.2–16.4) cm
2
. There was no significant correlation between the LGE extent 
and size of the low-voltage areas (<1.5 mV) in EAM (Pearson correlation: p=0.351). 
 
4.2.4  Electroanatomical map adjustment based on the late 
gadolinium enhancement 
 
In 16 patients with LGE (LGE+), the bipolar thresholds of low-voltage areas were 
individually adjusted in an attempt to match the localization and the size of the LGE. 
The median for the new bipolar threshold (Q1–Q3) was 1.5 (1.5–2.75) mV and the 
mean (SD) was 1.97±0.92 mV. Using the revised EAM thresholds, the mean size of the 
adjusted bipolar low voltage was 35.4± 27.6 cm
2 
(Table 10). Finally, the redefined 
bipolar EAM threshold showed a significant positive correlation with the LGE volume 
% (Pearson r=0.559). 
 
Table 10: Adapted EAM characteristics after adjustments according to the LGE. 
EAM, electroanatomical maps; LVA, low voltage area. 
 
Adapted EAM charactersitics  LGE (+); n=16 
Adjusted bipolar endo LVA size, (mean ± SD), cm
2
 35.4±27.6 
Adjsuted bipolar threshold, (mean ± SD), mV 1.97±0.92 








4.2.5 Ablation outcomes and predictors for success 
 
Acute success was achieved in 12 out of 16 patients (75%). Recurrence of VT was 
observed in seven (44%) patients during one year of follow-up. In patients with VT 
recurrence, the LGE volume was significantly larger than in those without VT 
recurrence: 12%±5.76% vs 6.9%±3.4%; p =0.049. The VT exits were found in areas 
with LGE in five out of seven patients with VT recurrence and in seven out of nine 
patients without VT recurrence. There was no difference in the surface of the low-
voltage areas between patients with recurrence and without (Table 11). 
 
Table 11: EAM and CMR characteristics of the patients with VT recurrences after 
ablation. CMR, cardiac magnetic resonance; EAM, electroanatomical maps; EDV, end-
diastolic volume; EF, ejection fraction; ESV, end-systolic volume; FWHM, full-width 
half maximum; IVS, interventricular septum; LGE, late gadolinium-enhancement; LV, 
left ventricle; LVA, low-voltage area; LVM, left ventricular mass; PW, posterior wall; 
VT, ventricular tachycardia. 
Procedural data VT recurrence, n=7 VT free, n=9 P 
CMR characteristics 
EF, % 35±12.6 36±11.3 0.839 
IVS, mm 10.9±2.3 10.9±2.1 0.937 
PW, mm 10±1.6 9.7±1.56 0.605 
LVEDV, ml 217±95 258±123 0.485 
LVEDVi, ml/m
2
 108±45 123±57 0.574 
LVESV, ml 146±88 173±103 0.581 
LVESVi, ml/m
2
 72±42 83±50 0.651 
LGE Volume (%) 12±5.76 6.9±3.47 0.049 
LGE Mass (FWHM), g 14.1±6.13 8.7±5.7 0.126 
LVM, g 115±33 147±48 0.204 
EAM characteristics 
Adapted bipol EAM, cm
2
 28±19 41±33 0.369 
Adapted bipol threshold,mV 2±0.95 1.94±0.95 0.91 






4.3 Results of the Reverse remodelling project 
4.3.1 Baseline characteristics 
 
A total of 13 patients (mean age 64±7 years, 38% male) were enrolled. CRT-D was 
implanted in 62%. Ten patients (77%) had non-ischaemic, one patient (8%) ischaemic 
and two patients (15%) had mixed aetiology based on the invasive coronary 
angiography and LGE pattern on CMR. Only one patient had prior acute myocardial 
infarction and PCI according to medical history. 
One patient showed no LGE, one patient had solely subendocardial LGE proving 
previous myocardial infarction, the two patients with mixed aetiology showed both 
subendocardial and midmyocardial LGE. Nine patients showed non-ischaemic LGE 
pattern: five of them had septal mid wall stripe pattern suggesting DCM, three patients 
showed focal patchy midmyocardial LGE in the insertion points suggesting the role of 
pressure overload, and one patient had subepicardial LGE suggesting prior myocarditis. 
 
4.3.2 Safety and image quality 
 
The follow-up scanning time including both AOO and biventricular pacing was 46±6 
minutes. During the CMR scan no supraventricular or ventricular arrhythmias were 
noted.  Atrial fibrillation started ten minutes after the CMR scan in one patient. On the 
same day pharmacological cardioversion using amiodarone was successful. Patient 
notification for atrial fibrillation or atrial tachycardia detection was switched on and 
Medtronic CareLink remote monitoring was initiated. Follow-up interrogation one 
month later showed no atrial fibrillation episode. None of the patients showed generator 
failure, lead failure, loss of capture, or electrical reset. Pre- and post-MRI device 
interrogation yielded no significant changes (mean change of battery voltage 0.0±0.0 V; 
pacing threshold: atrial: 0.0±0.1 V, right and left ventricular lead: 0.0±0.0 V; change in 
pacing impedance: atrial: -21.2±23.9 Ω, RV: -0.4±17.3 Ω, LV lead: -29.2±32.6 Ω, and 
change in shock impedance in CRT-D patients: -0.4±2.3 Ω). 
Left sided implantation was performed in all patients. Banding artefacts were present on 





images were also acquired achieving significant improvement of image quality. Precise 
analysis of SGE images was limited due to device artefacts in only two patients (three 
and two LV segments). Due to suboptimal image quality two patients were excluded 
from regional dyssynchrony analysis and one from global dyssynchrony and strain 
analysis. Device artefacts are presented on Figure 22. 
 
 
Figure 22: bSSFP (A-C) and SGE cine images (D,E) performed six months after CRT 
implantation. In case of CRT-P devices the generator related artefact on bSSFP images 
(yellow arrows) did not affect the heart, the lead related artefacts (white arrows) do not 
have any impact on the image analysis (A). In case of CRT-D devices generator related 
dark band off-resonance artefacts on bSSFP images are usually present (B,C). Therefore 
SGE images were obtained, which enables precise image analysis in majority of the 
cases (D), but two patients were excluded from the detailed analysis due to suboptimal 
image quality caused by generator related ferromagnetic susceptibility artefacts (orange 
arrows) (E). Heart and Vascular Center, Semmelweis University. bSSFP, balanced 






4.3.3 Reverse remodelling (Baseline vs BIV pacing) 
 
At 6-month follow-up two patients showed no symptomatic improvement (NYHA II), 
the conditions of 11 patients improved and were categorized in lower NYHA class 
(Figure 23).  
 
Figure 23: NYHA functional class at baseline and six months after CRT implantation. 
NYHA class improved in the vast majority of patients (85%) during the follow-up. 
NYHA, New York Heart Association Classification 
 
ProBNP levels (1186±863 vs 323±271 pg/ml, p<0.05) and QRS width (165±9 vs 
128±27, p <0.01) decreased. Based on the decrease of LVESVi, 11 patients were 
classified as super responders, one patient as responder and one did not reach the 15% 
LVESVi decrease (ΔLVESVi 9%). 
 
Comparing baseline and follow-up CMR parameters measured during biventricular 
pacing significant differences were found; a marked increase in LVEF and a decrease in 
LVEDVi, LVESVi and RVEDVi was detected. Left ventricular remodelling parameters 
such as relative wall thickness, 2D and 3D sphericity indices showed a noticeable 






Table 12: Characteristics and CMR parameters at baseline and at 6-month follow-up 
during biventricular pacing. HR, heart rate; BSA, body surface area; LV, left 
ventricular; EF, ejection fraction; EDVi, end-diastolic volume index; ESVi, end-systolic 
volume index; SVi, stroke volume index; COi, cardiac output index; HR, heart rate; Mi, 
mass index; RV, right ventricular; max EDWT, maximal end-diastolic wall thickness; 
3D sphericity (ESV/(4/3x π∗(end-diastolic LA diameter/2)3); 2D sphericity (end-
diastolic SA/LA diameter); RWT, relative wall thickness (2xEDWT/ end-diastolic LA 
diameter); GLS, global longitudinal strain; GCS, global circumferential strain; GRS, 
global radial strain, SD long TTP, mechanical dispersion as the standard deviation of 
time to peak longitudinal strain in 16 LV segments; SD circ TTP, mechanical dispersion 
as the standard deviation of time to peak circumferential strain in 16 LV segments; 
regional dyssynchrony, maximum differences in time between the peak septal and 







HR (bpm) 65±10 79±8 <0.001 
BSA (m
2
) 1.93±0.24 1.93±0.24 NS 
QRS (ms) 165±9 128±27 <0.01 
proBNP (pg/ml) 1186±863 323±271 <0.05 
CMR parameters 
LVEF (%) 27.0±7.1 45.7±7.6 <0.001 
LVEDVi (ml/m
2
) 144.3±28.6 88.8±20.0 <0.001 
LVESVi (ml/m
2
) 104.1±31.2 49.0±15.5 <0.001 
LVSVi (ml/m
2
) 37.7±7.2 39.8±7.3 NS 
LVCOi (ml/m
2
) 2.4±0.5 3.1±0.7 <0.05 
LVMi (g/m
2
) 83.6±15.4 77.5±16.5 NS 
RVEF (%) 62.2±5.4 62.0±4.1 NS 
RVEDVi (ml/m
2
) 64.4±12.2 58.2±10.7 <0.01 
RVESVi (ml/m
2
) 26.6±8.8 22.2±5.3 NS 
RVSVi (ml/m
2
) 39.6±7.0 36.0±6.4 NS 
RVCOi (ml/m
2
) 2.6±0.5 2.8±0.5 NS 
RVMi (g/m
2
) 15.0±2.3 12.2±2.9 NS 
Remodelling parameters 
max EDWT (mm) 10.8±1.9 11.7±1.2 NS 
3D sphericity 0.44±0.12 0.28±0.11 <0.01 
2D sphericity 0.70±0.11 0.61±0.12 <0.001 





Quantitative deformation assessment 
GLS (%) -13.4±4.7 -17.3±3.0 <0.05 
GCS (%) -10.8±4.5 -21.3±4.9 <0.001 
GRS (%) 25.9±11.7 38.8±10.8 <0.01 
SD long TTP (%) 17.6±2.9 15.8±4.1 NS 
SD circ TTP (%) 20.5±5.5 13.4±3.4 <0.001 
Regional dyssynchrony (ms) 362±96  104±66 <0.001 
 
Global left ventricular longitudinal, circumferential and radial strain values also showed 
a significant improvement. The analysis of global dyssynchrony showed that 
circumferential mechanical dispersion decreased (20.5±5.5 vs 13.4±3.4, p <0.001), 
while the longitudinal mechanical dispersion did not show significant change. 
Comparing regional dyssynchrony (defined by the maximum difference in time to peak 
septal and lateral transversal displacement) at baseline and at follow-up during 
biventricular pacing, it improved significantly (362±96 vs 104±66 ms, p <0.001).  
Decrease of regional dyssynchrony correlated with the decrease of LVESV (p <0.05,  
r =0.63) and with the increase of LVEF (p <0.05, r =0.66), and negative correlation 
between the decrease of regional dyssynchrony and RWT (p <0.05, r =-0.61) was found. 
 
4.3.4 Switching off the biventricular pacing (BIV vs AOO 
pacing) 
 
Analysing CMR parameters measured during biventricular pacing and with AOO 
pacing (BIV OFF), we found that after switching off the biventricular pacing LVEF 
(45.7±7.6 vs 37.9±7.4%, p <0.001) and LVSVi immediately decreased (39.8±7.3 vs 
33.1±8.7 ml/m
2
, p <0.001), and LVESVi immediately increased (49.0±15.5 vs 
55.5±16.9 ml/m
2
, p <0.001). 
GCS deteriorated significantly (-21.3±4.9 vs -17.7±5.6, p <0.05). There was a 
deterioration in terms of GRS (38.8±10.8 vs 32.9±7.6, p =0.055), whereas GLS showed 
no remarkable change (-17.3±3.0 vs -15.9±3.5, p =0.118). Examining mechanical 
dispersion, SD circ TTP increased (13.4±3.4 vs 17.0±4.4, p <0.05), while SD long TTP 





dyssynchrony was detected after switching off biventricular pacing (98±66 vs 335±148 
ms, p <0.001) (Figure 24). 
 
Figure 24: Comparison of CMR parameters at six months between biventricular and 
AOO pacing. LV, left ventricular; EF, ejection fraction (%); ESVi, end-systolic volume 
index (ml/m
2
); SVi, stroke volume index (ml/m
2
); GLS, global longitudinal strain (%); 
GCS, global circumferential strain(%); GRS, global radial strain(%), SD long TTP, 
mechanical dispersion as the SD of time to peak longitudinal strain in 16 LV segments 
(%); SD circ TTP, mechanical dispersion as the SD of time to peak circumferential 
strain in 16 LV segments (%); regional dyssynchrony, maximum differences in time 
between the peak septal and lateral transversal displacement (ms). 







5.1 Physiological adaptation mimicking pathological remodelling 
– the role of CMR in the differential diagnosis 
5.1.1 Overlapping features and differences between 
physiological and pathological remodelling  
 
Regular and intensive physical training as well as cardiomyopathies trigger electrical, 
structural and functional cardiovascular changes. These alterations may cause 
difficulties in the differentiation of physiological and pathological remodelling. 
 
Electrical alterations 
J-point elevation is considered as the most common, benign, training related ECG 
finding (132); it was present in 70-81% in our healthy athletes. In our healthy athletic 
cohorts isolated voltage criteria for left ventricular hypertrophy were observed in 19-
27%, while 55% of HCM patients showed positive Sokolow or Cornell index. Although 
ST-segment depression may be a finding on ECG even in athletes without any cardiac 
diseases, none of the athletes showed ST-depression and no pathological Q wave was 
present. T-wave inversion is considered to be a common ECG abnormality in athletes. 
According to the ESC recommendation T-wave inversion ≥2 mm in at least two 
adjacent leads is pathological, however the significance of T-wave inversion <2 mm is 
unclear (133). Only two percent of our healthy athletes had T-wave inversion in more 
than one contiguous leads, all of them in V1-V3 leads without signs of left ventricular 
hypertrophy. Eighty-two percent of HCM patients showed T-wave inversion.  
Repolarization abnormalities fulfilling major and minor TFC were detected in 65% and 
3% of sedentary ARVC patients, respectively. Depolarization abnormalities were less 
frequently present, 6% and 18% of sedentary ARVC patients showed depolarization 
abnormalities fulfilling major and minor TFC, respectively. All of the athletes with 
HCM showed at least one pathological ECG finding according to the 2014 ESC 





had Sokolow or Cornell index positivity and 90% showed T wave inversion on 12-lead 
ECG. Athletes with ARVC showed epsilon wave in 38%, TWI in lead V1-V2 and in 
V1-V3 leads was observed in 13% and 50%, respectively. Two athletes did not fulfil 
any repolarization or depolarization criteria, one patient had complete right bundle 
branch block. ECG alterations are common in sedentary patients and athletes with 
cardiomyopathies. However, lack of pathological ECG finding does not necessarily 
indicate pure physiological remodelling. 
 
Structural and functional alterations 
The physiological upper limit for left ventricular hypertrophy is considered as maximal 
EDWT of 16mm, therefore athletes with a maximal EDWT >16 mm may be considered 
to have pathological left ventricular hypertrophy (17, 47). In contrast with prior – 
mainly two-dimensional echocardiographic – data referring 2-15% of male athletes in 
the grey zone of hypertrophy (4, 17),
 
almost half of male athletes in our population 
reached EDWT of 13mm. According to previous observations, gender, age, BSA, level 
of dynamic and static component, training hours and intensity can also have a high 
impact on EDWT. Being members of the National or Olympic Team, our athletes 
represent an elite athlete population with extremely intensive and regular training. All of 
our athletes were performing high dynamic and at least moderate static sports. These 
characteristics of our athlete population and the fact that echocardiography may 
underestimate EDWT compared to CMR can be the explanation of the high rate of grey 
zone athletes (134, 135). Using echocardiography reliable delineation of LV wall 
significantly depends on the acoustic window, and EDWT could be underestimated 
because the epicardial border (especially in the LV free wall) is not visualized 
accurately. Moreover echocardiographic EDWT measurements are not always 
performed perfectly perpendicular to the myocardial center line. According to recent 
cardiac magnetic resonance (CMR) data phenotypic crossover between extreme forms 
of the athlete’s heart and mild forms of pathological hypertrophy is much more common 
than former literature suggested – the number can reach 23% among healthy young 
army recruits (136). Petersen and his colleagues have shown on a small cohort that LV 





differentiating physiological left ventricular hypertrophy from HCM (137). Based on 
our large population, sport indices established using both conventional and threshold-
based quantification method showed a good diagnostic accuracy even in the subgroup of 
athletes and HCM patients in the grey zone of hypertrophy. 
Although LV and RV systolic function is usually within normal limits in professional 
athletes, functional changes due to regular intensive training may include decrease of 
LV and RVEF. In our population less than 2% of athletes had LVEF<50% and LVEF 
between 50% and 55% was observed in more than one fourth of all athletes. Although 
none of the athletes in our population showed RVEF ≤45%, almost 15% of our athletes 
showed RVEF between 45% and 50%. Based on literature data RVEF between 40% and 
45% could be observed in 5% of elite athletes (138, 139). Preserved LV or RVEF was 
more common in male than in female athletes. 
Beside electrical and functional changes, prolonged endurance exercise may lead to 
structural changes in the right ventricle as well. Although CMR is the gold standard 
non-invasive method to measure RV volumes and function, there are only few studies 
investigating the role of athletic performance using CMR (64, 140, 141). Although it is 
well known, that competitive athletes have significantly larger RV volumes than 
recreational athletes or sedentary patients, current TFC contain no athlete-specific 
criteria, therefore misdiagnosis of ARVC in healthy athletes may occur. The right 
ventricular cut-off values for CMR parameters differentiating ARVC and athlete’s heart 
presented in our study could improve the diagnostic value of CMR in this special 
population. 
 
5.1.2 Gender-specific differences 
 
As in the last decades the number of women participating in competitive sport activities 
has been increased, the attention has been focused on the gender-specific differences in 
physiological remodelling. Electrical, structural and functional remodelling show 
significant differences between male and female athletes (142). The importance of 
gender-specific differences in athletes also confirms the fact, that the risk of SCD shows 





women (19, 20). Although the low number of athletes with HCM or ARVC in our 
studies does not allow us to draw powerful conclusions. Additionally, the representation 
of the female gender was modest, only 10% of our athletes with cardiomyopathies were 
female. 
Several studies have proven that sex has a remarkable effect on electrical remodelling. 
Sokolow-Lyon voltage criteria for left ventricular hypertrophy and left axis deviation 
are less common in female athletes compared to males (143). TWI in the precordial 
leads is 2-3 fold more common in females than males (143, 144). J point elevation in 
combination with anterior TWI is a common ECG pattern in male athletes whereas is 
rarely observed in female athletes (145). These observations are in agreement with our 
results, J point elevation and criteria for left ventricular hypertrophy (Sokolow or 
Cornell index) were more common in male athletes, while no clear gender-specific 
difference was found regarding the presence of TWI. 
Structural remodelling of the ventricles due to intensive exercise also shows differences 
between males and females. Based on a large cohort of athletes, Pelliccia and his 
colleagues observed that maximal EDWT is 23% lower in female athletes compared to 
male athletes. None of the females showed left ventricular hypertrophy ≥12mm 
confirming the observation that differentiation between HCM and athlete’s heart there is 
a less common clinical conundrum in females (83). In accordance with this observation, 
in our highly trained athletic population almost 50% of male athletes reached the grey 
zone of hypertrophy, this pronounced hypertrophy was absent in female athletes. In our 
study the AUC value of one evaluated in EDWT/LVEDVi using both conventional and 
threshold-based methods among female patients characterized a perfect classification 
result in female individuals, suggesting that differentiation between HCM and athlete’s 
heart in female individuals presents no remarkable difficulty. Recent echocardiographic 
data showed that absolute LV and RV dimensions are higher in males, but LV and RV 
diameters standardized to BSA are higher in females compared to males (143, 146). 
Although only limited CMR data are available about gender-specific normal left and 
right ventricular values for elite athletes (13, 18, 138), their results did not confirm these 






Although it is well known, that gender-specific differences in normal EDWT or mass in 
non-athlete healthy controls are present, HCM diagnostic criteria does not include 
gender specific cut-off values. In the revised Task Force Criteria for RVEDVi we do 
have different cut-off values in both genders. The question arises whether our cut-off 
values established for the differentiation between cardiomoypathies and athlete’s heart 
are applicable in both genders. Interestingly, despite the apparent gender-specific 
differences in cardiovascular sport adaptation our cut-off values for sport indices are 
applicable in both males and females. In the differentiation of athlete’s heart and 
ARVC, comparing male and female ROC curves of CMR parameters with the highest 
diagnostic accuracy (RVEF, RV mid strain, RV average strain, RV min strain) showed 
no significant difference. These results suggest that gender-specific differences 
regarding these parameters are negligible, so the presented right ventricular cut-off 
values are also applicable in both males and females. 
 
5.1.3 Role of novel CMR techniques in the differential 
diagnosis 
 
Threshold-based quantification method 
Previous studies already confirmed that threshold-based quantification in CMR provides 
an improved accuracy regarding left ventricular volumes and mass with an excellent 
intra- and interobserver variability. Moreover, it also contributes to a significant 
reduction in time required for post-processing (109, 147). As HCM patients show more 
pronounced left ventricular trabeculation and papillary muscles than healthy controls 
(148). Quantification methods enabling precise evaluation of trabeculae and papillary 
muscles may have a significant importance in this patient population. Literature data 
imply that as evaluation of trabeculae and papillary muscles can fundamentally change 
left ventricular parameters due to the large papillary muscles and pronounced 
trabeculation, in HCM patients analysis, which excludes papillary muscles and 
trabeculae from LV volume, is preferred (149, 150). Although it is also known that 





(151), earlier we lacked data regarding left ventricular normal values using 
quantification excluding trabeculae and papillary muscles from the blood pool.  
Our results confirmed the hypothesis that threshold-based method significantly alters 
left ventricular volumes and mass, moreover for sport index LVM/LVEDVi threshold-
based quantification provides significantly better diagnostic accuracy than the 
conventional method even in subjects in the grey zone of hypertrophy. In the small 
group of athletes with HCM in our study sport, indices were in the pathological range in 
a bigger proportion when we applied sport indices using threshold-based quantification 
method.  
 
Feature tracking analysis 
Myocardial strain analysis demonstrated a clear significance in both early diagnosis and 
risk stratification in cardiomyopathy patients (152, 153).  
Several CMR techniques were developed to estimate myocardial deformation. 
Myocardial tagging was the first method to achieve CMR based myocardial strain 
measurement. Cardiac magnetic resonance based strain assessment underwent a 
significant evolution in order to develop the clinical significance of the technique (154). 
Although myocardial tagging is a well validated technique with high reproducibility and 
also served as a gold standard method for validation, other strain measurement 
techniques including speckle-tracking echocardiography, the acquisition of additional 
images and the time consuming post processing has limited the widespread use of 
myocardial tagging in the everyday clinical routine (110). In the last decade, feature 
tracking has become a widely available technique to assess myocardial deformation 
without requiring further images. Left and right ventricular strain parameters can be 
established using the standard bSSFP images. The technique is based on the excellent 
blood-myocardium contrast on CMR images which enables the precise tracking of the 
endocardial contour (110). 
Right ventricular strain has become a popular technique both in diagnosis and risk 
stratification in RV pathologies such as right heart failure, pulmonary arterial 
hypertension and congenital heart diseases (155-157). However, because of the complex 





CMR enables perfect visualisation of the right ventricle, CMR based strain imaging 
may have an added value in RV pathologies.  
Although CMR is the gold standard method to evaluate RV function and volumes, 
subjective assessment of right ventricular wall thinning and wall motion abnormalities 
in the clinical routine represents the Achilles' heel of CMR. As feature tracking 
technique provides quantitative assessment of right ventricular function, it may have an 
added value in diagnosing ARVC. Based on recent literature data, global and regional 
right ventricular strain values of overt ARVC patients are decreased compared to 
healthy subjects, suggesting that feature tracking analysis may have an important added 
value in the diagnostic workup of ARVC patients (159-162). 
To best of our knowledge we are the first to report feature tracking based CMR strain 
values of highly trained athletes and report cut-off values to differentiate ARVC and 
athlete’s heart. Our results suggest that regional strain and strain rate of the right 
ventricular mid free wall are valuable discriminators even in patients with preserved 
RVEF and normal RV GLS. This fact highlights the significance of reporting CMR 
based strain parameters for differentiating athlete’s heart and ARVC. Although the 
moderate sensitivity of our cut-off values confirms that CMR is not an appropriate first 
line screening method. The good or excellent specificity enhances its role to prevent 
unnecessary disqualification because of overdiagnosing ARVC. 
 
Additional CMR techniques 
With the help of gadolinium based contrast administration CMR enables to detect 
fibrosis/scar which may be pathognomic for certain cardiomyopathies, moreover it 
tends to have significance in predicting sudden cardiac death. Prevalence of LGE in 
HCM patients is approximately 60%, myocardial fibrosis is most commonly present in 
the hypertrophic segments and in the right ventricular insertion points (163). Our 
sedentary HCM cohort presented a higher prevalence of LGE in the same localizations, 
while the presence of LGE was lower in athletes with HCM, and none of the athletes 
showed LGE. Detection of LGE in the hypertrophic segments or in the insertion points 
may help the diagnosis of HCM in athletes, but the lack of myocardial fibrosis does not 





positive predictive value, but low negative predictive value; in athletes with HCM even 
lower than in sedentary HCM patients. 
Although fibro-fatty replacement is a hallmark of ARVC and LGE can be present in 
approximately 30% of the patients (164), the current Task Force Criteria does not 
include presence of LGE as a criterion. Assessment of LGE especially in the thin right 
ventricular myocardium is challenging, additionally, the presence of left ventricular 
LGE is not specific as varying pathologies including sarcoidosis, myocarditis or DCM 
may mimic ARVC. Therefore, we have reason to believe that detection of LGE in 
suspected ARVC may have an important role, as it has been proved that VTs and VPBs 
often originates from the scarred regions indicating a relation between 
electrophysiological and structural abnormalities (165). In our ARVC cohort the 
prevalence of LGE was higher, two third of the patients showed LGE mainly in the left 
ventricle or in biventricular location, while only three of the eight athletes with ARVC 
showed LGE. Given the small sample size it might be misleading to draw definitive 
conclusions about the true prevalence of LGE in ARVC patients.  
LGE technique is a gold standard non-invasive method for assessing focal fibrosis. 
However, diffuse fibrosis may be underdetected on LGE images. Tissue 
characterization with the use of parametric mapping is an appropriate method to detect 
both focal and diffuse myocardial fibrosis. Native T1 mapping is feasible to tissue 
characterization even without the use of contrast agent. Post-contrast T1 mapping 
enables the quantification of extracellular volume. These techniques may play an 
important role in the differentiation of physiological and pathological remodelling. 
 
5.2 Electroanatomic and tissue characterization in patients with 
DCM 
5.2.1 Tissue characterization in patients with DCM using 
CMR 
 
Besides the visualization of fibrotic tissue, CMR enables quantification of LGE mass or 
volume using different techniques. The full-width at half maximum (FWHM) method 





hyperenhanced region, while different SD thresholds techniques defines scar tissue 
based on the mean signal intensity in the remote myocardium. Because of the high 
prevalence of diffuse interstitial fibrosis in the remote myocardium in DCM patients, 
SD threshold techniques may underestimate LGE volume. Based on this fact and the 
better reproducibility of FWHM method in our current study we applied FWHM 
quantification technique. 
Up to one third of DCM patients may show LGE mainly in the basal septum or the 
lateral wall and various LGE pattern such as linear mid-wall, subepicardial, focal patchy 
and diffuse pattern could be observed in DCM patients (115). In our current study 32% 
of DCM patients showed LGE most frequently in basal inferolateral, inferior and 
inferoseptal segments. Our results regarding the prevalence of LGE in patients with 
different ventricular arrhythmias (71% with VT, 5% with nsVT and none of the patients 
with VPBs showed LGE) emphasize the importance of LGE presence in VT prediction. 
It is well known that the presence of myocardial fibrosis correlates with functional 
parameters and clinical markers of heart failure in DCM patients. Moreover, large 
clinical trials have shown the predictive value of LGE pattern in DCM patients. Septal 
LGE is associated with increased risk of death and SCD in DCM patients even when the 
extent of LGE is small. Greatest risk may be present in case of concomitant septal and 
free-wall LGE (115).  
Besides all advantages, LGE technique has its limitations as diffuse interstitial fibrosis, 
which may contribute to arrhythmogenic substrate in DCM cannot be identified using 
traditional LGE technique. T1 mapping technique enables us to evaluate diffuse 
fibrosis. Furthermore, extracellular volume values closely correlate with collagen 
volume fraction quantified histologically from endomyocardial biopsies in DCM 
patients (166). Performing quantitative tissue characterization using T1 mapping may 
play an important role in the future as native T1 values are an independent predictor for 
ventricular arrhythmias (167). 
 







Areas of fibrosis in DCM can be visualized indirectly using bipolar and unipolar 
electroanatomic voltage mapping. It has been proven that homogenization of low-
voltage areas and elimination of the abnormal signals in patients with scar related VT is 
associated with better short- and long-term success rates in comparison to ablation 
targeting only clinical and stable VTs in patients with ischaemic aetiology with tolerated 
VT (168).  
In DCM patients, low-voltage areas are less frequently observed compared to patients 
with ischaemic aetiology. In DCM patients the scar is usually located midmyocardial or 
epicardial. Therefore scar may remain undetected during endocardial bipolar voltage 
mapping. Its visualization may require epicardial voltage mapping. The bipolar 
electroanatomic mapping has a narrower field of view and proved insensitive to 
delineate scars away from the endocardium (169). Data regarding optimal low-
amplitude definition in nonischaemic aetiologies are still controversial.  
The agreement between the identified bipolar low-voltage areas and LGE remained 
suboptimal. In order to improve the agreement between LGE and EAM, we adjusted the 
bipolar thresholds to match the EAM to the LGE areas. The newly defined median 
thresholds for the bipolar low-voltage maps were 1.5 mV, which are close to those 
observed in a large multicenter study (168). Because the adjusted bipolar thresholds 
showed significant correlation with LGE volume, it is possible that thresholds for the 
bipolar EAM should be adjusted in each patient depending on LGE volume. Higher 
thresholds should be used in patients with larger LGE volume and lower thresholds in 
patients with small LGE. 
 




Accurate characterization of the underlying aetiology is crucial in patients with 
ventricular arrhythmias as it may have serious prognostic and therapeutic significance. 
Identifying CMR-based scar pattern enables to distinguish between ischaemic and non-





recent study showed that CMR modifies the clinical diagnosis in approximately one 
third of patients with ventricular arrhythmias (170). 
 
Risk stratification 
As already mentioned earlier, the presence and extent of LGE may have an independent 
prognostic value in patients with DCM. In our current study patients with VT recurrence 
showed more extensive LGE compared to patients without VT recurrence, while no 
difference was found in the surface of LVAs in patients with or without VT recurrence.  
More detailed analysis of LGE images may provide more specific scar characteristics 
including extent and pattern of the scar tissue, scar transmurality and heterogeneity, size 
of the scar core and border zone, presence of conducting channels within the scar 
leading to more precise risk stratification (171-174). 
 
CMR to improve VT ablation success 
The role of CMR in patients undergoing VT ablation has been increased in the last 
decades. CMR imaging may play a role in preprocedural assessment of cardiac anatomy 
and myocardial scar tissue. LGE imaging enables to identify left ventricular regions that 
may be responsible for VT. In our study VT exits were presence in areas with LGE in 
75% of our patients. Previous studies have been demonstrated that critical VT isthmuses 
are located within LGE areas, suggesting the importance of CMR based ablation 
strategies. Siontis et al. have been proven that CMR performed before VT ablation in 
DCM patients showed a significantly higher rate of acute complete procedural success 
in comparison with patients without CMR (63% vs 24 %). After a median follow-up of 
7.6 months, 27% vs 60% of patients in the CMR and non-CMR group achieved the 
composite end-point of VT-recurrence, heart transplantation or death, respectively 
(175). Performing preprocedural CMR in order to establish the transmurality and pattern 
of LGE may help to identify the optimal access route. Patients with epicardial substrates 
show higher success rates in case of epicardial ablation. Identification of patients who 
may benefit from first-line epicardial ablation using LGE assessment has been reported 
to improve outcomes (176). Preprocedural CMR may minimize procedural 





Recently, as increased interest has noticed regarding pre- or intraprocedural integration 
of structural and electroanatomical substrate in order to guide ablation procedures. By 
integrating CMR images into the electroanatomic systems may facilitate a more targeted 
VT ablation approach especially in nonischaemic aetiology with epicardial or 
midmyocardial scar (173, 177). 
Due to providing excellent tissue-specific information CMR enables postprocedural 
assessment of the ablation’s effect by direct visualization of the ablation lesion in detail. 
Ablation lesions are characterized by presenting oedema, LGE and microvascular 
obstruction. It is possible to accurately assess the size and transmurality of the lesion. 
Real-time CMR-based assessment of ablation lesion formation (based on myocardial 
oedema, intramural haematoma or tissue temperature rise) could be a potential strategy 
to guide VT ablation (178). However, significant technological challenges (i.e. MR 
compatibility of electrophysiology catheters, appropriate processing of 
electrophysiology signals and improvements to simplify cardioversion in an MR 
environment etc.) impede the use of real-time MR-guided electrophysiological suite in 





5.3 The role of CMR in the detailed assessment of reverse 
remodelling after CRT implantation 
 
5.3.1 Assessment of the reverse remodelling using CMR 
 
In the clinical routine, assessment of the reverse remodelling achieved by CRT is 
performed using echocardiography. Although the many advantages of this imaging 
technique (cost-efficiency, low acquisition time, availability) have already been 
recognized, some disadvantages such as high inter and intraobserver variability and 
suboptimal image quality (especially in patients with poor echocardiographic window) 
still limits its applicability. Cardiac magnetic resonance is the gold standard method to 
evaluate ventricular volumes, masses and ejection fraction, and it enables a precise 
functional, mechanical and morphological assessment even in patients with suboptimal 
image quality on echocardiography. Owing to the low intra- and inter-observer 
variability, CMR enables optimal patient monitoring, and it may be used as part of a 
routine after CRT implantation and it may facilitate precise identification of patients in 
different “responder groups”. Despite the numerous advantages of CMR, potential 
disadvantage of CMR in CRT patient population that device related artefacts may 
hamper image analysis. Moreover, we have to deal with the fact that certain CRT 
manufacturers’ MRI safe mode does not include biventricular pacing as an option (179). 
Applying AOO or DOO RV only pacing during CMR examination may lead to 
unreliable measurements regarding LV function and mechanics. 
The metallic content of a PM or ICD generator in the magnet may lead to serious 
artefacts on bSSFP images. Dark band off-resonance and generator related 
ferromagnetic susceptibility artefacts may hamper image analysis. Recent literature data 
suggest that applying device-dependent imaging strategy using specific sequences (i.e. 
cine spoiled gradient echo) can eliminate or minimize the presence of device-related 
artefacts (180). The use of SGE technique eliminates the dark band off-resonance 
artefacts, and the remaining ferromagnetic susceptibility artefact usually does not 
affects the heart allowing detailed image analysis even in patients after left-sided CRT-





even when acquiring bSSFP images. Although banding artefacts were present on bSSFP 
images in all patients with CRT-D, applying SGE sequence appropriate image quality 
was reached. In CRT-D patients, only 2% of the LV segments were affected by serious 
banding artefacts on SGE, making dyssynchrony assessment more difficult, but not 
affecting volumetric and functional assessment despite the fact that all of our patients 
had left sided CRT-D. The relatively good image quality might be also explained by the 
size reduction of the generators during the last decades, because our study included 
devices implanted in the last few years only. 
In our study, CMR examination performed before CRT implantation and six months 
thereafter has proven that CMR is a valuable tool to monitor reverse remodelling in 
patients with CRT. Based on the decrease of LVESVi assessed using CMR, 11 patients 
were classified as super responders, one patient as responder and only one did not reach 
the 15% LVESVi decrease. Comparing baseline and follow-up CMR parameters during 
biventricular pacing, significant improvement was found in terms of LVEF, LVEDVi, 
LVESVi, RVEDVi and LV geometry. As CMR based deformation imaging also enables 
the assessment of global and regional strain values, it may also provide additional 
information besides standard volumetric and functional response. In our patient 
population a significant improvement in GLS, GCS and GRS, moreover global 
dyssynchrony expressed in circumferential mechanical dispersion decreased 
significantly. Regional dyssynchrony defined by the maximum difference in time to 
peak septal and lateral transversal displacement also decreased significantly. Proving 
that biventricular pacing during CMR is safe and feasible, we can conclude that CMR is 
an optimal method to precisely estimate reverse remodelling after CRT and may also 
open future perspectives in identifying optimal CRT settings. 
 
Prompt changes in LV function and mechanics 
High biventricular pacing rate is essential in CRT patients, because decreased LV 
pacing rate may lead to rapid deterioration of LV function. In our patients switching off 
the biventricular pacing and applying AOO pacing a prompt significant deterioration of 
LV mechanics and function was observed. Not to our surprise, no differences in 





remodelling is a long-term process. Although significant changes in the LVEF, LVSVi, 
LVESVi, GCS, mechanical dispersion and regional dyssynchrony were observed, 
parameters measured during AOO pacing did not reach the baseline values suggesting 
an existing memory. 
Based on these finding we can conclude that in order to utilize the advantages of CMR 
and measure the effect of CRT, avoiding asynchronous AOO or D00 RV pacing and 
applying biventricular pacing during CMR imaging is essential. 
 
5.3.2 The current role and future perspectives of CMR in 
CRT therapy  
 
CMR is a non-invasive modality, which enables precise quantification of function, 
structure and mechanics by assessment of LVEF, LV volumes, geometry, 
necrosis/fibrosis, global myocardial strain and dyssynchrony. Therefore, besides 
monitoring response to CRT, CMR may play an important role in optimal patient 




The single-center nature and the relatively limited number of patients are the major 
limitations of our studies. 
Additional potential limitation of our project entitled “Differentiation of pathological 
and physiological remodelling” may be the age differences. Our cardiomyopathy cohort 
represents an older population compared to the athletes, although age differences may 
not necessarily influence our results. There have been contradictory data originating 
from the studies on the effect of aging on strain values (181, 182). To eliminate the 
potential confounding effect of differences in age between HCM patients and athletes 
we made an effort to adjust our estimates for age. As physiological remodelling 
significantly depends on factors such as intensity of exercise, sport type and race, our 





of Caucasian athletes and mainly of sports with high static and dynamic components. 
Feature-tracking technique has its limitation including variability across different 
vendor software platforms. Standardization of the feature tracking technique remains an 
important challange in order to achieve the opportunity to the widespread use of feature 
tracking analysis in the clinical routine. Genetic mutation screening was not routinely 
performed in our cardiomyopathy patients. 
Potential limitation of our project entitled “Electroanatomical and tissue 
characterization” can be the applied scar quantification technique. Traditional methods 
to delineate LGE on CMR images depend on either the maximum signal intensity 
within the scar region, the mean signal intensity in remote regions and/or the standard 
deviation of signal intensity in remote regions. The extent of the scar quantified using 
the FWHM method in patients with non-ischaemic aetiology may be more variable than 
in patients with an ischaemic scar. Due to the fact that the reproducibility of FWHM 
seems to be better than scar signal intensity threshold based techniques. Furthermore, 
artefacts from the ICD devices can lead to false positive LGE findings, however, with 
the use of the wideband sequences, we were able to successfully distinguish between 
true LGE and false hyperenhancement. In terms of substrate visualization, T1 mapping 
can be more sensitive for the detection of diffuse fibrosis in patients with DCM than the 







Intensive and regular training can lead to physiological cardiac remodelling including 
LV hypertrophy and ventricular dilation, which may mimic pathological conditions 
causing differential diagnostic dilemmas. Based on our results half of elite healthy male 
athletes with very intensive and regular training may reach the grey zone hypertrophy, 
which may mimic HCM and cause diagnostic challenges in the everyday clinical 
routine. However, only minority of highly trained female athletes reached EDWT of 13 
mm suggesting that differentiation between HCM and athlete’s heart is a less common 
clinical conundrum in females. CMR based sport indices provide an important tool to 
diagnose HCM and distinguish it from athlete’s heart. Not only EDWT/LVEDViCQ but 
also our new indices determined using TQ (EDWT/LVEDViTQ and 
LVMTQ/LVEDViTQ) showed high diagnostic accuracy both in the whole cohort and in 
the male subgroup with an EDWT 13–16 mm. In our athletes with HCM, the only 
parameter falling into the pathological range was the LVMTQ/LVEDVTQ ratio. Our 
results highlight that RV dilatation in healthy endurance athletes may reach the 
proposed Task Force criteria in almost 95%. Therefore, elevated RVEDVi is an 
insufficient criterion for morphological diagnosis of ARVC. Besides establishing RVEF 
using CMR, RV strain analysis can provide an important tool to diagnose ARVC and 
distinguish it from athlete’s heart. CMR based regional strain and strain rate values may 
help to identify ARVC even in highly trained athletes with preserved RVEF and normal 
RV GLS. 
The link between structural and electrophysiological remodelling in cardiomyopathies is 
not yet fully understood. Assessing tissue and electroanatomic characteristics of DCM 
patients using CMR and electroanatomic mapping, we found that LGE was observed in 
approximately one third of the DCM patients with VA. Late gadolinium enhancement 
was seen mainly in patients with sustained VT. Comparing tissue and electroanatomic 
characteristics showed a fairly poor agreement between the distribution and the size of 
the LGE and bipolar low-voltage areas. No certain cut-off values for EAM could be 
identified. On the other hand, most VT exits were found in areas of LGE in patients 





As a result of successful cardiac resynchronization therapy, reverse remodelling may be 
detected in symptomatic heart failure patients with broad QRS and LBBB morphology. 
In our study, we proved that CMR imaging is feasible and safe in CRT patients with 
resynchronization on. Compared to baseline measurements, left ventricular reverse 
remodelling, improvement of systolic function, global strain, global and regional 
dyssynchrony were detected. Applying AOO pacing, we discovered an immediate 
deterioration of LVEF, LVESVi, LV strain and dyssynchrony. Biventricular pacing 
during CMR enables a more precise quantification of LV function, morphology and 
mechanics. Therefore, CMR imaging may contribute to a better understanding of the 









Cardiac remodelling is a compensatory process leading to functional and structural 
changes of the heart including scar formation, left ventricular dilation and geometrical 
changes with increasing spherical geometry. Similar changes may be present in 
cardiomyopathies or in athletes with marked physiological remodelling. 
As HCM and ARVC are leading causes of sudden cardiac death in young athletes, 
diagnosing these conditions in highly trained athletes is crucial. Novel CMR techniques 
may further improve the diagnostic accuracy and contribute to distinguish 
cardiomyopathies from marked physiological remodelling. We have first proven that 
sport indices such as EDWT/LVEDVi and LVM/LVEDV established using threshold 
based quantification may improve the diagnostic accuracy in athletes with suspected 
HCM. Our study has described first in the literature that CMR-based strain analysis is a 
useful tool to distinguish ARVC from athlete's heart. CMR-based right ventricular 
regional strain values may help to identify ARVC even in highly trained athletes with 
preserved right ventricular ejection fraction. Although it is known, that structural and 
electrophysiological remodelling are strongly related, to describe detailed information 
regarding tissue and electroanatomic characteristics of cardiomyopathy patients has 
been warranted. Based on our results, although only sub-optimal agreement could be 
found between the LGE and low-voltage areas, most VT exits were found in LGE areas 
in patients with sustained VT. Moreover, VT recurrence was influenced only by the 
LGE volume and none of the electroanatomic parameters. We have first proven that 
CMR imaging is a feasible and safe technique in CRT patients with resynchronization 
on, therefore precise assessment of reverse remodelling has become a clinical reality 
using biventricular pacing during CMR imaging. We have shown that in the absence of 
biventricular pacing (AOO pacing) immediate deterioration of function and mechanics 
occurs, therefore scanning with resynchronization on is crucial in this clinical setting.  
Based on our results using different novel CMR techniques may improve the diagnostic 
accuracy in athletes with suspected cardiomyopathies. Moreover, it may contribute to 
our better understanding of structural and electrophysiological changes in cardiac 







A kardiális remodelling a szívben funkcionális és strukturális változásokat 
(hegképződés, bal kamra tágulat és spherikus átalakulás) eredményező kompenzatorikus 
mechanizmus. Hasonló eltérések figyelhetők meg különböző cardiomyopathiákban, 
valamint az intenzív sporttevékenység hatására kialakuló sportszívben is.  
A fiatalkori sportolói hirtelen szívhalál hátterében leggyakrabban ARVC vagy HCM áll, 
ezért ezen állapotok diagnosztizálása élsportolók körében nagy jelentőségű. 
Vizsgálataink igazolták, hogy egyes új CMR technikák alkalmazása segítheti a 
cardiomyopathiák egészséges sportszívtől való elkülönítését. Elsőként igazoltuk, hogy a 
trabekulakvantifikációval meghatározott spotindexek (EDWT/LVEDVi és 
LVM/LVEDV) alklamazásával javítható a diagnosztikus pontosság HCM gyanús 
sportolók esetén. Vizsgálatunkban elsőként igazoltuk, hogy a CMR alapú strain analízis 
segítheti az ARVC és sportszív elkülönítését. A regionális jobb kamrai strain 
paraméterek alkalmazása megtartott jobb kamrai ejekciós frakciójú élsportolókban is 
segítheti az ARVC diagnózisának felállítását. 
Habár közismert, hogy a strukturális és eletrofiziológiai remodelling szorosan 
összefügg, a cardiomyopathiák strukturális és elektroanatómiai jellegzetességeiről szóló 
ismereteink hiányosak. Habár jelen vizsgálatunkban csak gyenge egyezést találtunk az 
alacsony feszültségű területek és a LGE-t mutató területek között, a legtöbb VT exit a 
LGE-t mutató területekre lokalizálódott. Továbbá kiemelendő, hogy a VT rekurrenciát 
egyedül a LGE kiterjedése befolyásolta, míg egyik elektroanatómiai paraméterrel sem 
mutatott összefüggést. Elsőként bizonyítottuk, hogy a CMR vizsgálat CRT implantációt 
követően biventikurális ingerlés alatt is biztonságosan kivitelezhető, és kiválóan 
alkalmas a reverz remodelling pontos megítélésére. Igazoltuk, hogy AOO ingerlésre 
váltva azonnali romlás mérhető a bal kamra funkcióban és mechanikában, igazolva a 
biventricularis ingerlés jelentőségét a CMR vizsgálat során. 
Eredményeink alapján megállapítható, hogy a különböző új CMR technikák 
alkalmazása nagyban segítheti a cardiomyopathiák és egészséges sportszív 
elkülönítését, továbbá hozzájárulhat a remodelling és reverz remodelling során 
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